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Abstract 
 
 
The effect of a single-bout of plyometric exercise on markers of bone turnover and Wnt 
signalling-related osteokines was studied in 20 younger, pre-menopausal women 
(23.142.33 years) and 20 older, post-menopausal women (57.904.35 years of age). 
Blood samples were obtained at rest (i.e., pre-exercise) and 5 min, 1h, and 24h post- 
exercise and were analyzed for C-terminal crosslinking telopeptides of type I collagen 
(CTX), osteoprotegerin (OPG), sclerostin and dickkopf-1 (DKK-1), and estradiol. 
Resting levels of CTX, OPG, and sclerostin were significantly higher while DKK-1 and 
estradiol were significantly lower in older compared to younger women. CTX was higher 
at 5 min post-exercise compared to pre-exercise in younger women (326.027.0 vs. 
292.029.0 pg/mL; p=0.049); however, no response was seen in older women. Sclerostin 
significantly decreased from 5 min (319.934.6 pg/mL) to 1h post-exercise (245.329.5 
pg/mL) but increased between 1h and 24h post-exercise (368.333.9 pg/mL) only in 
younger women. DKK-1 decreased in both groups. In younger women, the decrease was 
continuous from 5 min (2560.20120.65 pg/mL) to 24h post-exercise (2176.60115.29 
pg/mL, p=0.006). In post-menopausal women, the decrease was between pre-exercise 
(1949.69177.95 pg/mL) and 1h post-exercise (1549.82187.11 pg/mL, p=0.001) but 
returning to near pre-exercise levels 24h post-exercise. In the older women, OPG also 
decreased from pre-exercise (535.8 36.8 pg/mL) to 5 min post-exercise (475.139.0 
pg/mL; p=0.048) and remained lower than baseline for up to 24h post-exercise 
(505.032.4 pg/mL; p=0.046). No changes were seen in the younger women. These 
results suggest that in women, one session of plyometric exercise is sufficient to induce 
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significant changes in bone turnover and Wnt signalling related osteokines, however, the 
timing of the response varies significantly between age groups. 
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CHAPTER 1: LITERATURE REVIEW 
 
 
 
1.1 General Bone Physiology and Aging 
 
1.1.1 Bone Anatomy and Remodelling 
 
There are two types of bone found in the body, cortical and trabecular bone (1,2). 
Cortical bone is considered structural bone that determines the structure of the skeleton 
and is a heavily calcified bone (1). Cortical bone makes up 80 percent of the skeletal 
composition (1). Trabecular bone, 'spongy bone,' is less dense and makes up 20 percent 
of the skeletal composition (1,2). Trabecular bone is considered a more active bone that is 
found in the vertebrae, pelvis, and ends of long bones where more movement occurs, 
usually referring to the joint cavities. (2). 
The bone matrix includes the organic matrix, a collection of type I collagen, and 
the inorganic matrix, composed of calcium and phosphate (1,3). The inorganic matrix is 
largely associated with bone strength (3). Remodelling occurs through a tightly regulated 
sequence of bone breakdown, microdamage, and bone formation (1,2,4). Continuous 
mechanical loading causing microdamage to the bone structure initiates the constant 
remodelling of bone (2,5). Osteocytes, found within the bone matrix, differentiate 
precursor cells that play a large role in bone metabolism (6). One of the functions of 
osteocytes is to mediate the response to mechanical bone stress through the production of 
proteins, which influence the activation of the bone formation cells, the osteoblasts, and 
the activation of the bone resorption cells, the osteoclasts (4,5,7). Osteocytes, osteoblasts 
and  osteoclasts  are  important  in  the  regulation  of  the  remodelling  cycle  (2,4,6,7). 
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Osteoclastic resorption followed by osteoblastic bone formation determines the 
remodelling cycle (2,4,7). During the remodelling process, the osteoclasts, found on the 
surface of the bone, begin to resorb the bone matrix. The secretion of hydrogen ions and 
enzymes (cathepsin K and matrix metalloproteases) begin resorption of the bone matrix, 
breaking the bone structure down. This resorption creates a deficit within the matrix that 
will be replaced by the osteoblastic cells The osteoblastic cells, which are found lining 
the surfaces of bone, regenerate the bone matrix, initiating mineralization and increasing 
structural strength (1,2). 
1.1.2 Bone Changes in Adulthood 
 
After physical growth has completed, bone mineral density is maintained until 
approximately 50 years of age in women (8). The maintenance phase of bone remodelling 
indicates a balance between bone formation and bone resorption (8,9). However, as the 
body ages demineralization of bone occurs, which eventually leads to a decrease in bone 
mass. Loss of bone mass starts in early adulthood, approximately 50 years of age, and 
continues throughout adulthood (10–12). Bone loss is attributed to the uncoupling of 
bone resorption and bone formation (5,10,11). 
This decline in bone mass is amplified as women reach menopause (10,13). The 
increase in bone resorption occurs due to the decrease in the secretion or production of 
sex steroid hormones, and other endocrine changes as the body ages (1,5). These 
hormones also regulate the rate at which bone formation occurs, and therefore a decrease 
in bone formation is observed in the absence of sex steroids and endocrine factors (5). 
Moreover, the decline in bone formation rate can be indirectly attributed to the reduced 
production of osteocytes within the bone matrix, which promote bone formation by 
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responding to mechanical loading (5). Due to the factor of age, post-menopausal women 
are most likely to experience this imbalance in their remodelling ratio (5). 
1.1.2a Osteoporosis 
 
Osteoporosis is a disease defined by low bone mass and diminishment of the 
skeletal microarchitecture (14,15). Osteoporosis is a result of extreme low bone mineral 
density (BMD), which leads to the deterioration of bone strength and stability, increasing 
the rate of fragility fractures and injury (14,15). A variation in genetic composition and 
interactions with environmental factors cause osteoporosis (15). Osteoporosis is defined 
by a BMD score 2.5 standard deviations below the mean value for a young adult (14). 
The deteriorating bone disease is more common among the elderly population, and even 
more so in women, specifically post-menopausal women (14,15). Primary osteoporosis, 
having an unknown cause, and secondary osteoporosis, having a traceable etiology, can 
be either localized or generalized within the skeleton (14,16). The underlying mechanism 
is an imbalance in bone remodelling, hindering the accumulation of bone mass which 
results in insufficient bone mass and strength (14). Osteoporosis is a debilitating disease 
that affects quality of life significantly, requiring treatments to improve overall bone 
health. 
1.2.2b Estrogen and Menopause 
 
Estrogen, is a sex hormone that plays a crucial role in the development and 
regulation of the female reproductive system (17,18). Estrogen, more specifically 
estradiol, is important for bone development and maintenance of bone mineral density 
throughout various stages in life (18,19). Estrogen elicits a protective effect over the 
development and maintenance of bone through the inhibition of bone resorption (19). 
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Estrogen deficiency is correlated with longer osteoclast life and shorter osteoblast life 
(20,21). Thus, a deficiency in circulating estrogen in post-menopausal women may cause 
an increase in bone resorption through the promotion of prolonging osteoclastic activity 
(20). Estrogen interacts with and affects multiple mechanisms with respect to bone 
turnover and development (19). Estrogen represses osteoclastic cytokine production from 
immune cells (19,22), increases osteoblast proliferation while decreasing osteoblast and 
osteocyte apoptosis (23), and induces osteoclast apoptosis (21). 
Menopause is a natural process that occurs in women. Menopause occurs when a 
woman's menstrual cycle has ceased, leading to a loss of ovarian follicular function 
(8,24,25). Menopause tends to occur around 50 years of age; however, the timing is 
individual (8). Menopause stems from the reduction or lack of circulating estrogen (26). 
Estrogen, a sex steroid, increases the sensitivity of bone to mechanical loading during 
reproductive years, i.e., before menopause, through its influence on osteoblastic cells (3). 
During menopause, estrogen deficiency occurs, which affects bone turnover rate (3,27). 
Post-menopausal women experience an increase in bone resorption due to the deficit in 
circulating estrogen, and this increase in bone resorption increases bone loss compared to 
bone replenishment, and therefore, compromises the skeletal structure (3,8,27). This, in 
turn, causes an overall reduction in bone mass and mineralization (3,8,26,27). The 
compromise to the skeletal system in post-menopausal women causes an increased risk 
for low bone mineral density, and an increased fragility and fracture rate (8,27). In short, 
a decrease in estrogen lessens bone formation and increases the risk of deterioration of 
bone, leading to osteoporosis (8,27). This effect indicates that women have a high risk of 
developing osteoporosis after menopause (8). 
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1.2 Markers of Bone Turnover 
 
Markers of bone turnover include those that reflect formation and those that 
reflect resorption. Formation markers of bone turnover include total alkaline phosphatase 
(ALP), bone ALP, osteocalcin (OC), procollagen type I C-terminal peptide (P1CP), and 
procollagen I intact N-terminal (P1NP) (28). These markers play a role in different stages 
of maturation and differentiation of osteoblasts (28). Plasma tartrate-resistant acid 
phosphatase (TRAP 5b), N-telopeptides of type I collagen (NTX), and C-terminal 
crosslinking telopeptides of type I collagen (CTX) are bone resorption markers that 
reflect osteoclast activity (28). These markers are all considered bone turnover markers, 
as they demonstrate the activity of the osteoblasts and the osteoclasts during bone 
metabolism (28). Although all these markers are good indicators of the activity of both 
the osteoblasts and osteoclasts, CTX and P1NP are well accepted bone turnover markers 
that are recognized by the International Osteoporosis Foundation (IOF) as they are by- 
products of osteoblastic or osteoclastic cell activation (28,29). P1NP concentrations 
indicate the synthesis of protein within bone tissue, the activation of osteoblasts,  
allowing the concentrations of P1NP serum to be a direct indicator of bone formation 
(29). CTX, is also a direct indication of osteoclast activity, indicating the activity of bone 
resorption, as CTX is secreted from osteoclasts when they are activated. (30–33). More 
importantly, as strong indicators of bone turnover (28,29), both P1NP and CTX are the 
most sensitive markers in the post-menopausal population as indicators of bone 
metabolism and osteoporotic tendencies (28). 
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1.2.1 C-terminal Crosslinking Telopeptides of Type I Collagen (CTX) 
 
The organic matrix found within bone is primarily made up of collagen, which 
provides the skeleton with its biochemical structure (31). Collagen crosslinks are peptides 
that are crucial biochemical markers of bone turnover, more specifically bone resorption, 
that have been created through the process of collagen degradation (30–33). CTX, is a 
specific type of collagen crosslink that is an indicator of bone resorption and can be 
measured in both urine and blood (30–33). Increased levels of CTX are highly correlated 
with a higher fracture rate due to the increase in bone resorption, weakening the overall 
bone structure (32). Further correlations have been observed between levels of CTX and 
consequential bone loss within post-menopausal women (31)., CTX is indicative of bone 
resorption (30–33). 
1.2.2 Procollagen Type I N-Terminal Peptide (P1NP) 
 
P1NP is a type I collagen, which is the main component of bone (34). P1NP is the 
most specific bone formation marker, as it is a predictor of various phases of osteoblastic 
activity, and is an indicator of bone metabolism (29,35,36). P1NP serum concentrations 
are indicative of the synthesis of the most abundant protein of bone tissue, type I collagen 
(29). During bone formation, the osteoblasts secrete the precursor procollagen molecule, 
P1NP, indicating a direct correlation between serum P1NP and bone turnover activity 
(29). Levels of P1NP are highly reliable and are not influenced by food intake or renal 
function but may be influenced by circadian rhythm (29,36). Furthermore, P1NP is a 
good predictor of bone turnover rates as well as a monitoring tool in forecasting the 
presence of osteoporosis in post-menopausal women (36). 
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Figure 1: Bone Turnover Marker Associations (adapted from (1)). 
 
 
1.3 Bone Specific Signalling Pathways 
 
1.3.1 Wnt Signalling Pathway 
 
The Wnt/β-catenin signalling pathway is involved in the development and 
maintenance of various organs and tissues including bone (37–39). In bone, the Wnt 
pathway is largely associated with osteoblastogenesis, which determines bone formation 
(37,40). The Wnt pathway encompasses 19 glycoproteins that are involved in gene 
transcription leading to bone formation (37,39). The canonical Wnt signalling pathway 
can be defined as a pathway dependent on the stabilization of β-catenin protein (37–40). 
As shown in Figure 2, downstream activation of the Wnt pathway begins with the Wnt 
ligand molecule binding to the low-density lipoprotein-related receptor 5 and low-density 
lipoprotein-related receptor 6 (LRP5 or LRP6) or a frizzled transmembrane receptor (37– 
40). The binding of the Wnt molecule activates the protein dishevelled (Dsh) triggering 
downstream phosphorylation of glycogen synthase kinase-3β (GSK-3β), which inhibits 
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GSK-3β from phosphorylating β-catenin (39,40). The inhibition of GSK-3β facilitates β- 
catenin to initiate nuclear translocation, which targets gene transcription leading to bone 
formation, (38–40). This occurs as β-catenin is building up within the cytoplasm, able to 
reach its threshold, allowing β-catenin to enter the nucleus of the cell. The Wnt pathway 
stimulates the process of cell proliferation, renewal of stem cells, stimulation of 
preosteoblast replication, and enhancement of osteoblast activity, increasing bone mass 
and functionality of bone cells (37,40). Thus, the Wnt/β-catenin signalling pathway is a 
complex anabolic mechanism that is involved in a diverse process to develop bone mass 
(37). 
 
 
 
 
Figure 2: Wnt/β-catenin Signalling Pathway (adapted from (41)). 
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There are various bone specific cytokines, i.e., osteokines, which influence the Wnt/β- 
catenin signalling pathway. Sclerostin is a glycoprotein that is coded by the SOST gene; 
it is part of a family of proteins that have the shared ability to provoke bone 
morphogenetic protein (BMP) activity (1,5,6,42–44,41). The promotion of BMP activity 
allows for changes in bone mineral density and structure of bone (6). The expression of 
the SOST gene occurs within the matrix, allowing the secretion of sclerostin from the 
osteocytes (45). Sclerostin is synthesized by the osteocytes within the bone matrix in 
response to a reduction in mechanical loading and age-related hormonal (eg. estrogen) 
changes (1,42–44,41,45,46). Sclerostin inhibits osteoblast differentiation, thus decreasing 
bone formation (1,5,42–44,41). Specifically, sclerostin acts as a Wnt signalling antagonist 
through binding to the LRP-5/6 progenitors, inhibiting the Wnt molecule from binding to 
the LRP-5/6 receptor (5,42–44,41,45,46). Inhibition of the Wnt pathway (Figure  3) 
results in decreased osteoblastogenesis and bone formation (6,42,44,45). A reduction in 
bone formation induces the uncoupling of remodelling (1,2). Serum concentrations of 
sclerostin are shown to be significantly higher in post-menopausal women compared to 
pre-menopausal women (42,47,48). Women experience a 2.4 fold increase in resting 
serum sclerostin levels as they age, indicating that sclerostin levels are positively 
associated with age (48). However research on this topic is still limited. Future studies are 
needed to fully understand the role of sclerostin on bone adaptation during aging, 
particularly in women due to the decreased estrogen post-menopause, which has been 
associated with higher secretion of sclerostin (47). 
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Figure 3: Sclerostin and DKK-1 inhibiting the Wnt/β-catenin signalling pathway 
(adopted from (41)). 
 
 
 
Dickkopf-related protein 1 (DKK-1) is another antagonist of Wnt, which plays a 
role in the inhibition of bone formation similar to that of sclerostin (7,49,50). DKK-1 is a 
central regulator of osteoblastic activity and is expressed by the osteoblasts and 
osteocytes (7,51). Similar to sclerostin, DKK-1 causes a blockage of the LRP5/6 receptor 
sites and does not allow the Wnt molecule to bind (7). This blockage results in the 
inhibition of bone formation (Figure 3), influencing the balance of resorption and 
formation involved in bone remodeling (1,2,7). Increased concentrations of DKK-1 have 
been known to enhance osteoclastogenesis (52).  Mechanical loading has been observed 
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to reduce the concentration of DKK-1 and therefore reduces the effect of the protein's 
inhibition on the Wnt pathway (49). Furthermore, serum concentrations have been 
observed to be higher in post-menopausal woman compared to women of the same age 
who have not experienced menopause (53). Similarly, concentrations of DKK-1 have 
been linked to estrogen deficiency-medicated osteoporosis, an endocrine factor associated 
with menopause (53,54). However, the expression of DKK-1 and its relation with aging 
and bone mineral density is not well established, and therefore further exploration to 
determine the influence is necessary (7). 
1.3.2 OPG-RANKL Pathway 
 
The interaction between Osteoprotegerin (OPG) and the receptor activator of 
nuclear factor kappa-β ligand (RANKL) is a key pathway that regulates the outcome of 
bone remodelling (1,55,56). The OPG-RANKL pathway dictates a large portion of bone 
turnover, specifically regulating bone resorption (1,55,56). 
RANKL plays a role in the process of differentiation of osteoclast precursor cells 
into mature osteoclasts (4,57,55,58). RANKL is expressed by osteoblasts on the 
extracellular surface of their plasma membrane, as well as by bone marrow stromal cells 
and T cells within the bone matrix (4,57,56). In response to mechanical strain, the 
osteocytes recruit osteoclasts to induce bone resorption, activating the secretion of 
RANKL from the osteoblastic cells (4). RANKL's expression is up-regulated to activate 
bone resorption (58). Once secreted, RANKL is bound to one of two receptors: the 
receptor activator of nuclear factor kappa-β (RANK) or OPG (4,57,55,56,58). As shown 
in Figure 4, the role of bone turnover is determined by the interaction of RANKL to 
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either the OPG receptor, inhibiting the activation of osteoclastogenesis, or the RANK 
receptor, activating the osteoclast to resorb the bone matrix (4,57,55,56,58). 
RANK is a protein expressed on the surface of the osteoclasts (4). The interaction 
between RANKL and RANK is responsible for the differentiation, survival, and 
activation of osteoclasts, causing bone resorption (4). The binding of RANKL to RANK 
activates the down-stream process of bone resorption within the bone matrix 
(4,57,55,56,58). 
 
 
 
 
 
Figure 4: The OPG-RANKL interaction (adopted from (4)). 
 
 
OPG is considered a bone protector, as it acts as a decoy receptor for RANKL 
(4,57,55,56,58). OPG essentially blocks the RANKL protein from binding to RANK by 
attaching itself to the RANKL molecule, and therefore indirectly inhibiting bone 
resorption  from  occurring  (4,57,55,56,58).  OPG  is  down-regulated  and  primarily 
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expressed through bone marrow stromal cells as well as osteoblasts (56,58). Estrogen 
stimulates the secretion of OPG from the osteoblasts and inhibits the production of 
RANKL (4). This interaction affects the post-menopausal female population because the 
estrogen production is reduced, allowing the RANKL-RANK complex to occur due to the 
decreased amount of OPG, increasing bone resorption mechanisms (4). 
 
The Wnt/β-catenin signalling pathway influences RANKL and OPG (37). When 
the pathway is activated by the Wnt molecule, expression of OPG is stimulated through 
up-regulation of OPG from the osteoblasts, which results in indirect suppression of bone 
resorption (37). As well, the activation of the Wnt/β-catenin signalling pathway causes a 
cascade of down-regulation of RANKL expression in the osteoblasts, ultimately leading 
to an indirect suppression of bone resorption (37). 
 
1.4 Factors Impacting Bone Integrity 
 
1.4.1 Uncontrollable Factors 
 
Many factors contribute to the accumulation or deterioration of bone mass; some 
are controllable, and some are not. Uncontrollable factors are those that cannot be 
changed or influenced by outside sources. Sex is an uncontrollable factor that can 
influence bone mass (59). Men have wider bones with a greater cortical mass compared 
to women (59). Women tend to have more slender skeletal frames that have lower bone 
strength and less accumulation of bone mass, indicating that fracture risk is 2.5 times 
great in women compared to men (59). Less bone mass accumulation among women can 
lead to higher likelihood of fragility fractures in elderly women compared to elderly men 
(60). Ethnicity can also play a role in the skeletal structure: fracture rates among black 
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women are 50% less than in white women (59). However, fracture rates among men of 
both ethnicities are comparable (59). Skeletal age is an uncontrollable factor associated 
with bone structure (60). There are three age-related processes that can cause 
deterioration of bone mass (60). Trabecular bone decreases with age by about 50% over 
the lifespan through the thinning of the trabeculae (60). Furthermore, net resorption is 
increased at a rate of 0.5% /year as the skeletal structure ages (60). As well, cortical 
BMD is reduced contributing to bone loss with aging (60). Age is a large uncontrollable 
contributing factor that causes  an increase in  bone turnover rate  in favour of  bone 
resorption (60). Uncontrollable factors are critical to bone integrity; however, they are 
just that: uncontrollable. 
1.4.2 Controllable Factors 
 
Controllable factors associated with osteokines can influence bone accrual 
through active management. Exercise, which will be discussed in detail later, is a large 
controllable factor that greatly influences bone turnover (61). Exercise activates 
osteocytes in favour of bone formation, acting as a preventative measure or a proactive 
measure to promote more accumulation or maintenance of bone mass through influencing 
bone turnover (61). Dietary consumption plays a crucial role in the bone remodelling 
process (62). A balanced energy state, where energy expenditure and energy intake are 
equal is when bone metabolism is able to thrive (62). Furthermore, the intake of specific 
vitamins and nutrients that promote bone turnover are essential to bone health and are 
controllable dietary factors (63). Vitamin D and calcium have an interdependent role in 
terms of bone metabolism (63). Vitamin D is found in oily fish, egg yolk, and meat; 
however, its greatest source is in the skin, where is activated through exposure to the 
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sun’s ultraviolet B rays (63). The recommended daily dietary allowance is 600 IU for 
individuals who are 1-70 years of age, and 800 IU for individuals over the age of 70 (63). 
Vitamin D promotes the intestinal absorption of calcium (63). Calcium, a controllable 
factor of bone, is a large component of bone accrual (64). Calcium is essential to bone 
development and the increase or maintenance of bone integrity (64). The daily 
requirement of calcium is 1000mg for adults; however, many individuals are not meeting 
the recommended daily allowance (64). Increasing calcium consumption to the daily 
recommended allowance has been demonstrated to increase BMD upwards of 16% 
compared to individuals who are severely under-consuming calcium (64). 
Estrogen therapy is a controllable factor that elicits a large bone turnover response 
(65). Positive effects of estrogen therapy in women approaching menopause or post- 
menopausal women have been observed to increase BMD and reduce fragility fracture 
risks (65). This controllable factor is able to maintain BMD and in some cases increases 
BMD up to 2.4% through the equalizing effect of bone remodelling, creating a more 
balanced ratio between resorption and formation of bone (65). 
Oral contraception has been observed to have a neutral or possible beneficial 
effect on bone mass in women after 30 years of age (66). Oral contraceptives are seen to 
be more influential in later years of pre-menopause as they prevent the activation of bone 
turnover though increasing estrogen within the body, causing an imbalance of resorption 
to formation, ultimately increasing BMD (66). However, oral contraceptives have been 
known to increase the risk of fracture in women who have been taking them for longer 
durations (66). Likewise, medication such as glucocorticoids, thiazolidinediones, and 
unfractionated heparin have been known to cause a decrease in bone formation (67). 
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Others such as medroxyprogesterone acetate and aromatase inhibitors have been 
determined to reduce estrogen levels and production (67). Older women should consider 
the impact on the skeletal integrity of a medication before consuming it, and furthermore 
should consider choosing medication that does not impact bone (67). 
 
1.5 Exercise and Bone 
 
1.5.1 Exercise and Bone Mineral Density 
 
Exercise is considered the most influential non-pharmacological method for 
improving or maintaining bone mass (68,69). Exercise is both a preventive and a 
therapeutic strategy to improve bone mineral density and work against the weakening of 
bone due to natural aging processes (70,71). During exercise, the various stresses on the 
body induce mechanical loading (jumping, running, resistance training etc.), which 
allows bone to initiate the bone remodelling process. However, not all exercise modalities 
and intensities are equally efficient in increasing bone mass (61,72,73). Furthermore, 
there are uncertainties with respect to the intensity, duration, and frequency of exercise 
that elicit an optimal osteogenic exercise response (74). Mechanical strain as a result of 
physical activity causes bone metabolism to react and initiate bone remodelling in favour 
of bone formation (73). Bone structure and strength must be able to endure the 
mechanical forces of everyday life to avoid fracture or deterioration of bone mass (72), 
allowing for bone tissue to experience higher mechanical forces that increase bone mass 
during physical activity (75). 
It is well established that individuals of all ages and sexes who participate in sport 
or physical exercise have higher bone mass, bone strength, and a greater osteogenic 
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potential compared to individuals who are not physically active (73,76–78). In particular, 
individuals of all ages and sexes who participate in high-impact dynamic sports, which 
apply various directional impacts, have a higher osteogenic response compared to other 
individuals participating in less impactful exercise (73,76). Although it has been observed 
that mechanical strain stimulates proliferation of osteoblasts in order for bone adaptation 
to occur, further research is needed to obtain a comprehensive understanding of the 
mechanisms involved (77). 
1.5.2 Plyometric Exercise 
 
Plyometric exercise encompasses explosive jumping and mechanical force that 
can generate force up to seven times an individual's body weight (73, 75). Due to the high 
mechanical load on bone, which activates bone remodelling, plyometric exercise is 
considered the most valued modality of exercise for improving bone mass (73). 
Previously, one study has shown positive changes in bone mass and reduction in 
deterioration of bone mineral density in a population of post-menopausal women as a 
result of a plyometric exercise intervention (79). However, there is limited data in older 
populations, including post-menopausal women, on the bone response to an acute 
plyometric exercise (73). More investigation is needed to better understand the direction 
and magnitude of the bone response to acute plyometric exercise (73). 
1.5.3 Exercise and Bone Turnover 
 
Many observations have been made in terms of acute exercise and its impact on 
bone turnover and bone health in numerous intensities and modalities (80–83). These 
observations have shown that response may vary with respect to type, duration, and 
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intensity, of exercise (80–83). Therefore, the influence that an acute exercise bout has on 
markers of bone turnover is not well understood. 
Despite the variation among the studies, some collective conclusions can be made 
(34). The magnitude of stimulation for both osteoclasts and osteoblasts are also mode, 
intensity as well as duration dependent, demonstrating differences in immediate and 
delayed impact of exercise on bone turnover markers (34,84–91). Furthermore, a sex and 
age difference is indicated in various studies that show that exercise does not influence 
markers of bone turnover in the same magnitude in varying populations (80,81,83,92). 
Both males and females exhibit a varied response to an exercise stimulus while there 
seems to be an age variation within the same sex in response to the same exercise 
protocol (80,81,83,92). Generally speaking, not all exercise protocols and durations will 
elicit the same response in all populations, with potential differences between sexes and 
between age groups. 
CTX in particular has demonstrated some varying results in response to exercise. 
However, in an acute training session CTX has demonstrated no change in serum levels 
post-exercise in a group of male and female young (20 years of age) adult athletes (85). 
As well, a decrease in CTX was seen in young women 30 minutes post-exercise in a 
resistance whole body vibration study (91). Lastly, an increase in CTX serum levels were 
seen 30 minutes post- 1h cycle ergometer at 80% VO2max in young male triathletes (93). 
Seeing as these results are widely different, some conclusions can be speculated. CTX 
can be influenced by an acute exercise protocol, however the magnitude and direction of 
that response is determined by population as well as exercise modality and intensity 
variation. 
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1.5.4 Exercise and Osteokines Related to Wnt Signalling Pathway 
 
1.5.4a Sclerostin 
 
Osteocytes regulate inhibition of bone formation via secretion of sclerostin 
(43,94,95), indicating that mechanical strain influences the osteocyte expression of 
sclerostin (45). A linear relationship between mechanical strain and concentration of 
sclerostin has been observed. In animal studies, sclerostin has been found to evoke the 
regulation of mechanotransduction within bone cells (95,96). However, human studies 
using exercise to increase the mechanical loading on bone are scarce. A cross-sectional 
study in adults indicates a correlation between physical activity and lower levels of 
sclerostin (97). However, in a young female population, pre- and post-menarche, an acute 
bout of plyometric exercise did not induce significant changes in serum sclerostin neither 
immediately or up to 24h post-exercise (80). Similar to the girls, conducting the same 
protocol, young boys saw no significant response in serum sclerostin after the plyometric 
exercise protocol but an immediate increase post-exercise was observed in young men 
(81). As there are no published studies examining the response of sclerostin to an acute 
bout of exercise in post-menopausal women, the acute response to high-impact exercise 
in this population is unknown. However, no significant changes in sclerostin were found 
following a 12 month physical training program in post-menopausal women (45-65 
years) (98). As there were varying results from these previous studies, the association 
between exercise and sclerostin is not clear, and that there may be age and sex related 
variations in the sclerostin response to exercise. It would be expected that a decrease in 
sclerostin post-exercise should be seen. 
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1.5.4b DKK-1 
 
DKK-1 is another protein that inhibits the Wnt pathway in a similar way to 
sclerostin (50). Therefore, it is postulated that DKK-1 would react to mechanical strain 
to a comparable magnitude (94). There is one human study on the response of DKK-1 to 
a plyometric exercise protocol. Specifically in girls, DKK-1 concentrations were 
significantly higher at rest in the pre-menarcheal compared to the post-menarcheal groups 
(80). As well, a decrease from baseline to 1h post-exercise was demonstrated in both 
groups and remained decreased even 24h post-exercise (80). However, little is known 
about the role of DKK-1 in exercise, and thus, more research is needed to understand the 
response of DKK-1 to mechanical loading (99). 
1.5.3c OPG 
 
OPG serum concentrations  have been examined  within varying  exercise 
modalities, populations, and duration of intervention with inconsistent results (71,80– 
82,98). It is thought that increasing mechanical strain and stress on bone compared to a 
resting level would result in a response in OPG serum levels (82). An increase in OPG 
concentrations, leading to a reduction in osteoclastic activity, lessening bone resorption, 
and increasing overall bone mass and strength, would be observed post-exercise 
intervention (82). In pre- and post-menarcheal girls, no response occurred after a single 
bout of plyometric exercise (80). In contrast, both adult women and men experienced an 
increase in OPG after a marathon run (82). The variability found in these studies suggests 
that OPG’s response to mechanical strain elicited by an exercise intervention is not the 
same in terms of magnitude or direction in all populations and for all modalities and 
durations of exercise. 
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1.5.5 Summary 
 
Markers of bone turnover are often used to examine the dynamic course of bone 
turnover during acute exercise (100). Thus, many observations have been made in terms 
of acute exercise of various intensities and modalities, and its impact on markers of bone 
turnover. For example, strenuous weight-bearing exercise is capable of stimulating a 
response, increasing bone resorption activity over bone formation in adults (100). An 
acute plyometric exercise trial was performed in boys, girls, adolescent girls, and men to 
determine the influence that this exercise had on bone biomarkers (80,81). It was 
determined however, that only men experienced an increase in sclerostin concentrations 5 
min post-exercise while no other groups had a significant time-effect (80,81). In response 
to the same protocol, no significant time effect was determined in OPG and RANKL 
concentrations in girls and adolescent girls (80). Table 1 presents the relevant studies on 
the post-exercise responses of the markers and osteokines of interest. 
Despite the variability among the studies, some collective conclusions can be 
made (34). The magnitude of stimulation for both osteoclasts and osteoblasts are also 
exercise-dependent, demonstrating  a  difference  in  immediate and  delayed  impact  of 
exercise on bone turnover (34). However, there are still many unanswered questions in 
regards to the bone response to an acute bout of exercise, in general and in association 
with endocrine and other age related changes across the lifespan. 
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Table 1: Response to Acute Exercise in Bone Turnover and Osteokines. 
 
Study 
Reference 
Population Exercise Results 
Dekker et al. 
2017 (80) 
14 Pre-menarcheal 
(10.5 years) 
 
12  Post-menarcheal 
girls (15.0 years) 
Acute Plyometric 
Exercise over 24 
hours 
No group effect or time main effect in girls or 
adolescence for sclerostin and OPG. 
DKK-1 was higher in the pre-menarcheal girls 
compared to the post-menarcheal girls. 
In both groups, DKK-1 decreased from 
baseline to 1h post-exercise and remained 
lower than baseline 24h post-exercise. 
Falk et al. 2016 
(81) 
12 Boys 
(10.2 years) 
 
17 young men 
(22.7 years) 
Acute Plyometric 
Exercise over 24 
hours 
Resting levels of sclerostin higher in boys 
than men. 
Sclerostin 5 min post-exercise in men. 
Ziegler et al. 
2005 (82) 
11 women and 20 
men, recreational 
runners 
Pre- and post- 
either a marathon 
or a short 
distance run 
(42.195 km vs. 
15.8 km) 
OPG increased only in the marathon group. 
Herrmann et al. 
2007 (85) 
32 male and female 
athletes and 
controls 
Incremental 
anaerobic cycle 
ergometer 
No changes in CTX serum levels post- 
exercise. 
Sherk et al. 2013 
(91) 
10 recreationally 
active women 
(20.7 years) 
Resistance 
training and 
whole-body 
vibration 
CTX concentrations post vibration and 30 min 
post resistance in the combination group. 
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CHAPTER 2: INTRODUCTION TO RESEARCH PAPER 
 
 
Osteoporosis is a chronic disease characterised by diminishment of the bone 
quantity and quality leading to an increase in fracture rate (100). Unfortunately, 1 in 3 
women and 1 in 5 men experience an osteoporotic fracture, and 1.4 million Canadians 
have been diagnosed with osteoporosis (100). The bone quality and quantity are the 
contributing factors to the overall bone health and provide better understanding of the 
tissue involved in bone metabolism and strength (100). Bone quality is referring to the 
mineralization, materials or geometry, of the bone. Bone quantity refers to the mass of the 
bone, the bone mineral density, which makes up about 74% of bone strength in adults. 
Thus, the geometry, volume and cortical thickness of bone as well as the bone mass are 
determinants of bone strength and can attribute to the overall variability of bone strength 
(100). 
Accumulation and loss of bone mass occur in various stages in a woman’s 
lifespan (1,13). Once physical growth has been reached, bone mass is maintained 
throughout adulthood through bone remodelling until women begin menopause (10,13). 
Remodelling occurs when osteoblasts, the bone-forming cells, replace the deficit that 
osteoclasts, the bone resorption cells, have produced (1,2,4,7). Bone mass is, therefore, 
maintained through a delicate balance/coupling between bone resorption and bone 
formation (1,2,4). As a result of menopause, there is an accelerated decline in bone mass 
caused by the uncoupling of bone resorption and formation, when the rate of 
replenishment of bone by the osteoblasts does not match the loss of bone by the 
osteoclasts (1,5,10,11,13). This uncoupling is due to the lack of circulating estrogen, 
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which influences the balance of remodelling (3,8,26,27). Specifically, estrogen elicits a 
protective effect over bone by indirectly inhibiting bone resorption (19) and inducing 
osteoclast apoptosis (21). In addition, estrogen has been found to repress 
osteoclasticogenic cytokine production from immune cells (19,22) and to increase 
osteoblast proliferation while decreasing osteoblast and osteocyte apoptosis (23). These 
changes in bone turnover that occur with menopause are reflected in increasing bone 
resorption markers like CTX (87,90–93). 
The Wnt signalling pathway is a multifaceted anabolic system that is involved in 
various organs and tissues including bone (37–39). In bone, the Wnt pathway is largely 
connected to the activation of osteoblastogenesis, causing bone formation (37,40). The 
Wnt ligand molecule activates the pathway through binding to the low-density 
lipoprotein-related receptor 5/6 (LRP5 or LRP6) or a frizzled transmembrane receptor 
(37–40). Once bound, activation of the protein dishevelled (Dsh) triggers the downstream 
phosphorylation of glycogen synthase kinase-3β (GSK-3β) (39,40). GSK-3β is inhibited 
but Dsh and does not activate the phosphoalation of (39,40). The build up of β-catenin in 
the cytoplasm initiates nuclear translocation in to the nucleus, which targets gene 
transcription in favour of bone formation (38–40). The activation of gene transcription 
stimulates cell proliferation, renewal of stem cells, stimulation of osteoblastic replication, 
and enhancement of osteoblast activity, which leads to increased bone mass and 
functionality of bone cells (37,40). 
Osteocytes play an important role in sensing variations in mechanical loading, and 
coordinating signals of resorption and formation (40). Sclerostin has been suggested as 
one way that osteocytes regulate this osteogenic response to loading, by acting as a 
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negative inhibitor of the Wnt/ß-catenin pathway, reducing osteoblast activity and 
therefore bone formation (101). Previous research conducted with animal models has 
shown that mechanical loading of the bone results in decreased sclerostin levels, whereas 
mechanical unloading results in increased levels (102). This decrease in sclerostin after 
loading is a crucial step to promote osteogenesis. Failure to downregulate sclerostin after 
loading impedes the activation of the Wnt pathway and therefore osteoblast activity is not 
increased (95). Dickkopf-related protein 1 (DKK-1) is another Wnt-inhibiting protein that 
plays a crucial role in the inhibition of bone formation (7,49,50). DKK-1 is expressed by 
both the osteocytes and the osteoblasts as it regulates the activity of the osteoblastic cells 
(7,51). DKK-1 binds to the LRP-5/6 receptor inhibiting the Wnt molecule from binding 
(7). Elevated serum DKK-1 concentrations have been observed to enhance 
osteoclastogenesis, increasing activity of the osteoclastic cells (52). In contrast, 
osteoprotegerin (OPG) is an anabolic downstream product of the Wnt-signalling pathway. 
OPG is considered a bone protector and acts as a decoy receptor to the receptor activator 
of nuclear factor-kappaβ ligand (RANKL) (4,57,55,56,58). Specifically, OPG blocks 
RANKL from binding to the RANK receptor, indirectly inhibiting bone resorption 
(4,57,55,56,58). 
Limited research has focused on comparing resting levels of DKK-1 in young and 
older adults, specifically pre- and post-menopausal women. On the other hand, it is well 
established that sclerostin resting levels are significantly higher in post-menopausal 
women in comparison to their younger counterparts (42,47,102). One explanation for the 
higher sclerostin levels post-menopause is the inverse relationship between estrogen and 
sclerostin, in which decreased estrogen results in higher secretion of sclerostin (47). In 
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contrast, higher daily physical activity levels are associated with lower serum sclerostin 
levels, probably due to the increased mechanical loading on the bones (97). 
Despite the above cross-sectional studies suggesting that exercise influences bone 
through an increased mechanical loading, very few studies have examined the sclerostin 
and DKK-1 response to an acute bout of exercise, in general, and in association with 
changes in bone turnover markers. Falk et al (81) were the first group to examine the 
sclerostin response to an acute bout of plyometric exercise in boys and men, pre-pubertal 
and young men (20 years). A significant increase in sclerostin levels immediately after 
plyometric exercise was present, however only in men. The same plyometric protocol led 
to higher OPG from pre- to 24h post-exercise in pre-and early pubertal boys (103) On the 
other hand, in pre- and post-menarcheal girls, ages 8-16 year, the plyometric exercise 
protocol resulted in no change in OPG, while DKK-1 decreased up to 24h post-exercise 
(47). Sclerostin did not change following plyometric exercise in either girls (47) or boys 
(103). 
In the above studies, the osteokine response to exercise was studied in children in 
relation to older age groups (males and females separately). However, an examination of 
these osteokines in response to plyometric exercise, and in relation to changes in bone 
turnover markers, between younger, pre-menopausal women as compared to older, post- 
menopausal women is yet to be performed. Insight into this response has important 
implications; a better understanding of the bone’s response to mechanical loading can 
contribute to preventative strategies against bone diseases and age-related osteopenia. 
Therefore, the purpose of this study was to examine the acute response of CTX, and 
osteokines related to Wnt signalling pathway such as sclerostin to a single bout of high 
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impact exercise in younger versus older women. Based on previous findings, and the 
theoretical assumptions on the potential effects of mechanical loading applied by acute 
exercise on CTX and Wnt related osteokines outlined in Table 2, it is expected that CTX, 
sclerostin and DKK-1 will decrease, while OPG will increase, in the hours following the 
exercise in both the younger and older women. 
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Table 2: Response to Acute Exercise; CTX and Wnt Related Osteokines. 
 
Bone Turnover 
and Osteokines 
Influence of Exercise Bone Response 
CTX ↑Mechanical Loading 
↓ CTX 
↓ Osteoclast Activation 
Sclerostin ↑Mechanical Loading 
↓ Sclerostin 
Wnt Signalling uninhibited 
DKK-1 ↑Mechanical Loading 
↓ DKK-1 
Wnt Signalling uninhibited 
OPG ↑Mechanical Loading 
↑ OPG 
↑ Inhibition of Bone Resorption 
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CHAPTER 3: METHODS 
 
 
3.1 Participants 
 
This study and its procedures were approved by the Brock University Biosciences 
Research Ethics Board (REB-14-267 KLENTROU). A total sample size of 40 healthy, 
normal weight, recreationally active women were recruited: 20 younger (pre-menopausal) 
women (23.12.3 years) and 20 older (post-menopausal) women (57.94.3 years). 
Participants were recruited through circulating poster advertisements and by word of 
mouth based on the following inclusion criteria: (1) had a body mass index <30; (2) were 
non users of pharmaceutical agents that directly affect bone; and (3) had no facture within 
the last six months. In addition, all post-menopausal women self-reposted being at least 2 
years post-menopause, and were asked to obtain medical clearance from their physician. 
All participants in the pre-menopausal group self-reposted being eumenorrheic, and were 
tested during their follicular phase. The majority of younger women (17 of 20) were also 
on birth control. The hormonal profile of the birth control method used was noted in the 
medical questionnaire, but was neither an inclusion or exclusion criterion. 
 
3.2 Study Design and Procedures 
 
The two-day study protocol involved two visits to the Applied Physiology 
Laboratory at Brock University. Participants were asked to refrain from caffeine and 
alcohol for 8 hours prior to visiting the laboratory and to not perform any vigorous 
activity for 24 hours prior to their first visit and during the three-day protocol. All visits 
30  
to the laboratory were scheduled in the morning and in fasted state. This was to account 
for circadian rhythm and fasted to have less influence on the biochemical markers. 
Upon their first arrival to the laboratory, the participants were informed of the 
research protocol and asked to sign an informed consent and complete a medical history 
questionnaire. Following this, a baseline, resting blood draw was taken using 
venipuncture of the median cubital vein. After the first blood sample, participants were 
provided with a standardized breakfast, a granola bar, a juice box, and a banana, followed 
by anthropometric measurements: height (cm), weight (kg), waist and hip circumference 
(cm), jump height (cm), and body composition. Maximal Jump height, an average of 3 
jumps, was measured at 33.61.2 cm for the younger women and 22.70.9 cm for the 
older women; therefore, making the box height 35.00.0 cm for the younger women and 
26.70.7 cm for the older women. This was calculated using the participants jump height, 
measured by a vertical jump height measuring device, and having the box height be equal 
to or greater than 100 percent of their jump height (closes to measurement as possible). 
This was to ensure that the ground reaction forces produced from the box jump were 
sufficient for each participant to elicit a measureable response without compromising the 
safety of older participants. The women then performed a plyometric exercise trial 
followed by 2 post-exercise blood samples: 5 min, 1h, and returned the next day for a 24h 
post-exercise. The participants then completed a series of questionnaires including the 
Godin-Sheppard Leisure Time Exercise Questionnaire, and a Food Frequency 
Questionnaire between the various blood draws during the first visit as visually illustrated 
in Figure 5. 
31  
 
 
 
 
Figure 5: Study Protocol. 
 
 
3.3 Exercise Trial 
 
The acute exercise plyometric trial was designed to elicit an impact on bone 
through various exercises performed in a circuit as previously used in our laboratory 
(80,81). It began with 5-min warm-up on the cycle ergometer and dynamic stretching. 
The participants were familiarized with the exercises through a detailed explanation and a 
demonstration of each exercise. The exercise protocol consisted of a total of 128 jumps 
organized into five circuit exercise stations with three minutes of rest between each 
station. The circuit contained box jumps, lunge jumps, tuck jumps, single-leg hops, and 
jumping jacks. Each participant was instructed to rotate through each of the five stations 
3 times for 3 sets of 8 repetitions of these jumps, with the exception of the single-leg 
hops, which were performed as 2 sets of 8 repetitions on each leg. The box jump height 
was adjusted to the individual’s jump height measured; therefore, allowing the participant 
to jump at least 100% percent of their jump height to elicit a ground reaction force within 
the bone. The participants were also encouraged to go at their own pace to ensure comfort 
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and reduce injury during the protocol. A five-minute cool down using static stretching 
completed the exercise protocol. 
3.4 Measurements 
 
3.4.1 Anthropometry 
 
Measurements of body mass, body mass index (BMI), and percent body  fat 
(%BF) were taken using the InBody520 bioelectrical impedance analysis (BIA) system 
(Biospace.228). Participants were asked to be well hydrated before the BIA measures, 
and were asked to void all liquids before the measurement. Height was measured using a 
stadiometer to the nearest 0.1 cm. Jump height was measured using a Vertec Jump Height 
measurement device to the nearest 1.0 cm. Waist and hip circumference were measured 
using a measuring tape (under clothing for the waist circumference and over clothing for 
the hip circumference) to the nearest 0.1 cm. These measures were taken with no shoes 
and in exercise clothing. To maintain measurement consistency, the same investigator 
performed all anthropometric measures. 
3.4.2 Physical Activity and Dietary Intake 
 
Physical activity was assessed by the Godin-Shepard Leisure Time Exercise 
Questionnaire using intensity categories of light, moderate or strenuous exercise (104). 
This questionnaire can be used in male and female populations of all ages. The Godin- 
Shepard Leisure Time Exercise Questionnaire estimates the weekly physical activity 
metabolic equivalent (METs/week) based on the number of 15 min blocks at each 
intensity level. The number of blocks at each intensity level is then multiplied by known 
energy consumption values to determine metabolic equivalents (104). This questionnaire 
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is simple to follow, accurate, and easy to analyse, and it has been demonstrated to be 
valid and reliable in male and female paediatric, adolescent, and adult populations (104). 
Participants’ dietary intake was determined using the Block Questionnaire 2014, 
which is designed to determine nutritional habits over the last 6 months. Portion sizes 
were provided in a pictorial display to maintain consistent portion size between 
participants. The questionnaires were analysed by Nutrition Quest (Nutrition  Quest, 
USA) to provide estimations of total caloric intake (kcal/day) and energy balance 
(kcal/day). These values were used to determine energy balance for the participants. 
3.5 Serum and Plasma Analysis 
 
Four venous blood samples were taken: at rest, and at 5 min, 1h, and 24h 
following the exercise. At the first-time point, (i.e., resting sample) 18 ml of blood was 
collected, and 10 ml of blood was collected at all post-exercise blood draws. The serum 
for the biochemical markers was collected in vacutainers with an SST serum separator 
and the plasma samples for the endocrine markers were collected in vacutainers that 
contain K2EDTA. 
At all blood draw instances, the hematocrit was measured to determine changes in 
plasma volume. This was to ensure the alteration in the markers measured were true 
measures due to the exercise intervention and not influenced by plasma volume changes. 
Both serum and plasma samples were allowed to clot in the laboratory for 30 minutes at 
room temperature before centrifuging. The vacutainers were centrifuged at 3000 x gravity 
for 15 minutes to separate the serum and plasma from the red blood cells. The serum was 
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stored at -80⁰C until all samples were collected. Plasma samples were stored in cryotubes 
and frozen at -80⁰C until all samples were collected and were ready for analysis. 
CTX was assayed using a Human ELISA kit (E-EL-H0835, Elabscience, 
Bethesda, MD, USA). The intra-assay coefficient of variation average was 6.44% for all 
5 plates. The average inter-assay coefficient for 5 plates was 6.54%. Sclerostin was 
assayed using four Human SOST/Sclerostin Quantikine ELISA kits (DSST00, R&D 
Systems, Minneapolis, MN, USA). The intra-assay coefficient of variation average was 
7.68% between the 6 plates, and the inter-assay coefficient of variance between the 6 
plates was 7.10%. The results of the bone marker assays were assessed in duplicate using 
a Synergy HT Biotek spectrometer and Gen 5 Software at a wavelength of 450 nm with a 
correction wavelength of 570 nm. All samples from an individual participant were 
analyzed on a single plate. DKK-1 and OPG were analyzed using Magnetic Luminex 
Assays (LXSAHM, R&D Systems, Minneapolis, MN, USA). The inter-assay coefficient 
of variation average was 6.32% and 8.23%, respectively for all 5 assays. The intra-assay 
was 5.09% and 5.71%, respectively for all 5 assays. All assays were analyzed using the 
Luminex MAGPIX reader as well as the MAGPIX software. Estrogen was measured 
using am ELISA kit (KGE014, R&D Systems, Minneapolis, MN, USA), with an inter- 
assay coefficient of variation was 11.67%. 
 
3.6 Statistical Analysis 
 
Normal distribution was screened and verified using the Kolmogorov-Smirnov 
test of normality, as well as for skewness and kurtosis. Group differences for 
anthropometric  measures,  dietary  intake,  physical  activity,  and  resting  biochemical 
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concentrations were tested using an independent t-test. For other normally distributed 
variables, a series of two-way repeated measures (group X time) ANOVAs were used to 
assess group differences over time in the biochemical markers. When significant main 
effects for group were found, pairwise comparisons for each time point were made using 
the Tukey post-hoc test. In the event of a significant time effect, further pairwise 
comparisons were made using paired t-tests to determine significant differences between 
time points within each group. In the case of CTX, which was not normally distributed 
based on the normality criteria, non-parametric tests were used to examine the difference 
between groups (Mann-Whitney tests), as well as the time effects within groups 
(Friedman tests with Wilcoxon tests for post hoc pairwise comparisons). 
 
Note that from a total of 160 blood samples (40 participants x 4 time points) there 
were 16 missed samples. Missing values were imputed using the group’s mean value for 
that particular time point. In addition, if the assumption of sphericity for a particular case 
was not met, the Greenhouse-Geisser test of significance was used. If the assumption of 
equality of covariance was not met, a Pillia’s Trace test of significance was used. 
Significance was accepted at an alpha level of <0.05 for all analyses. Statistical Analysis 
was performed using SPSS version 22 for Windows. 
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CHAPTER 4: RESULTS 
 
 
 
4.1 Baseline measurements 
 
The physical characteristics of the participants are presented in Table 3. Post-menopausal 
women were significantly older and had significantly higher BMI, waist, and hip 
circumference. There was no other significant difference between the groups. 
 
 
Table 3: Physical Characteristics of participants in both age groups. 
 
 
 Pre-Menopausal 
(n=20) 
Post-Menopausal 
(n=20) 
P-value 
Age (years) 23.14 0.51 57.90 0.97 <0.0001* 
Weight (kg) 62.63 1.83 65.63 2.03 0.280 
Height (cm) 165.70 1.88 163.90 1.58 0.468 
Body Fat Percentage (%) 24.71 1.24 30.99 1.90 0.008* 
BMI 22.74 0.54 24.70 0.79 0.046* 
Waist Circumference (cm) 71.62 1.35 79.21 1.81 0.002* 
Hip Circumference (cm) 90.31 2.46 99.78 1.93 0.005* 
Waist-Hip Ratio 0.79 0.01 0.78 0.01 0.729 
All Values are Expressed as Mean Standard Error of Mean; *indicates a significant group difference 
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Energy intake and expenditure for both the pre- and post-menopausal women are 
depicted in Table 4. There were no significant differences between the groups in terms of 
their physical activity energy expenditure, total energy intake, fat, protein, or 
carbohydrate intake. 
 
 
Table 4: Energy intake and energy expenditure of participants in both age groups. 
 
 
 Pre-Menopausal 
(n=20) 
Post-Menopausal 
(n=20 
P-value 
Total Energy intake (kcal/day) 1777.75 135.11 1509.70 126.31 0.156 
Fat (g/day) 65.81 5.66 63.51 6.40 0.788 
Protein (g/day) 68.64 5.77 61.10 4.46 0.311 
Carbohydrates (g/day) 197.18 17.98 171.31 17.10 0.304 
Physical Activity Energy 
Expenditure Metabolic 
Equivalent (METs/week) 
75.52 9.13 70.75 9.02 0.712 
All Values are Expressed as Mean Standard Error of Mean; *indicates a significant group difference 
 
 
 
Morning, resting baseline concentrations of all markers, osteokines and hormones 
for both the pre- and post-menopausal women are shown in Table 5. First, estradiol was 
lower in older women, confirming their post-menopausal status. Post-menopausal women 
have significantly higher levels of CTX, sclerostin and OPG compared to the pre- 
menopausal women. Moreover, post-menopausal women demonstrated a significantly 
lower level of DKK-1 at baseline compared to their pre-menopausal counterparts. 
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Table 5: Resting concentrations of Bone Turnover Markers and Osteokines. 
 
 Pre-Menopausal 
(n=20) 
Post-Menopausal 
(n=20) 
P-value 
CTX (pg/ml) 292.0 29.0 431.0 33.0 0.05* 
Sclerostin (pg/mL) 264.56 26.61 542.69 64.58 <0.0001* 
DKK-1 (pg/mL) 2404.74 136.73 1949.69 177.95 0.049* 
OPG (pg/mL) 372.45 15.14 535.79 36.85 <0.0001* 
Estradiol pg/mL 97.23 12.41 67.36 4.75 0.028* 
All Values are Expressed as Mean Standard Error of Mean; *indicates a significant group 
difference; CTX= C-terminal crosslinking telopeptides of type I collagen; DKK-1= dickkopf-1; 
OPG=Osteoprotegerin. 
 
 
 
 
4.2 Exercise response 
 
At each time interval, plasma volume was determined to support the significance 
of a time-alteration for the bone turnover markers and osteokines measured. It was 
determined that no significant plasma change was observed in any of the participants, 
indicating that values of the markers measured are that of true magnitude and not 
influenced by plasma volume changes (Table 4). 
Table 6: Plasma volume as a percent of total blood volume for each time point. 
 
Baseline 
(%) 
5-min 
post-exercise (%) 
1 hour 
post-exercise (%) 
24 hours 
post-exercise (%) 
0.58 0.03 0.58 0.03 0.58 0.03 0.59 0.03 
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A significant time effect was observed for CTX using the Friedman test for 
repeated measures with the Wilcoxon post hoc comparisons indicating a significant 
increase between baseline and 5 min post-exercise in the young women. Unfortunately, 
the Friedman non-parametric analysis does not test the time-by-group interaction. 
However, no significant changes were found in the older women (Figure 6a). 
Furthermore, for ease of interpretation, Figure 6b summarizes the percent change in the 
median concentrations of CTX from pre- to post-exercise in each group. 
 
 
 
 
 
 
Figure 6a: C-terminal crosslinking telopeptides of type I collagen (CTX) concentration 
from pre- to 24h post-exercise in younger (N=20) and older (N=20) women. Values are 
expressed as mean  standard error of mean; *indicates significance in the Wilcoxon 
post-hoc pairwise comparisons. 
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Figure 6b: Percent changes in C-terminal crosslinking telopeptides of type I collagen 
(CTX) from pre- to 24h post-exercise in younger (N=20) and older (N=20) women. 
Values are expressed as mean standard error of mean (note that when the standard error 
is <2% the error bars are not shown on the graph). *indicates significance in the 
Wilcoxon post-hoc pairwise comparisons. 
 
 
 
 
In addition to a group-effect observed in the resting levels of sclerostin, there was 
a significant time effect and a significant group-by-time interaction. In pre-menopausal 
women, sclerostin significantly decreased from 5 min to 1h post-exercise, then 
significantly increased from 1h to 24h post-exercise (Figures 7a and 7b). There were no 
significant time-related changes in the post-menopausal group. 
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Figure 7a: Sclerostin concentration from pre- to 24h post-exercise in younger (N=20) 
and older (N=20) women. Values are expressed as mean standard error of mean; 
*indicates significance in the Tukey post-hoc pairwise comparisons. 
 
 
 
 
 
 
Figure 7b: Percent changes in Sclerostin from pre- to 24h post-exercise in younger 
(N=20) and older (N=20) women. Values are expressed as mean standard error of mean 
(note that when the standard error is <2% the error bars are not shown on the graph). 
*indicates significance in the Tukey post-hoc pairwise comparisons. 
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A significant time effect and a significant group-by-time interaction were 
observed in DKK-1. In the pre-menopausal women, there was a significant decrease from 
5 min to 24h post-exercise (Figures 7a and 7b). In the post-menopausal women, a 
significant decrease in DKK-1 concentration presented from baseline to 1h post-exercise 
and from 5 min to 1h post-exercise In addition, a significant increase from 1h to 24h post- 
exercise was observed in the post-menopausal women (Figures 8a and 8b). 
 
 
 
 
 
 
Figure 8a: Dickkopf-1 (DKK-1) concentration from pre- to 24h post-exercise in younger 
(N=20) and older (N=20) women. Values are expressed as mean standard error of 
mean; *indicates significance in the Tukey post-hoc pairwise comparisons. 
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Figure 8b: Percent changes in Dickkopf-1 (DKK-1) from pre- to 24h post-exercise in 
younger (N=20) and older (N=20) women. Values are expressed as mean standard error 
of mean (note that when the standard error is <2% the error bars are not shown on the 
graph). *indicates significance in the Tukey post-hoc pairwise comparisons. 
 
 
 
 
There was a significant time effect and a group-by-time interaction for OPG. 
Specifically, in post-menopausal women OPG significantly decreased from baseline to 5 
min and continued to be lower than baseline both 1h and 24h (Figures 9a and 9b). 
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Figure 8a: Osteoprotegerin (OPG) concentration from pre- to 24h post-exercise in 
younger (N=20) and older (N=20) women. Values are expressed as mean standard error 
of mean; *indicates significance in the Tukey post-hoc pairwise comparisons. 
 
 
 
 
 
 
 
Figure 9b: Percent changes in Osteoprotegerin (OPG) from pre- to 24h post-exercise in 
younger (N=20) and older (N=20) women. Values are expressed as mean standard error 
of mean (note that when the standard error is <2% the error bars are not shown on the 
graph). *indicates significance in the Tukey post-hoc pairwise comparisons. 
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CHAPTER 5: DISCUSSION 
 
 
To our knowledge, this is the first study to compare bone markers and Wnt 
signalling related osteokines at rest and in response to an acute bout of plyometric 
exercise over a 24-hour duration between younger, ages 20-30 in their follicular phase, 
and older women, 50-65 post-menopause. Compared to the younger women (pre- 
menopausal), at rest CTX, sclerostin and OPG were significantly higher in the older 
women, and DKK-1 and estrogen were significantly lower in the older women (post- 
menopausal). Second, there was a significant time effect for all markers and osteokines 
but the responses varied between groups. CTX increased post-exercise, but only in the 
younger women, sclerostin significantly decreased 1h post-exercise and then increased 
24h post-exercise only in young women, while DKK-1 continued to decrease in both 
groups up to 24h following plyometric exercise, and OPG also decreased post-exercise 
but only in the older women. 
 
5.1 Bone Markers and Osteokines at rest 
 
At rest, levels of serum CTX were higher in the older (post-menopausal) women 
compared to the younger (pre-menopausal) women. This is indicative of a group 
difference in CTX that may reflect differences in the rate of bone turnover (30–33). More 
specifically, post-menopausal women are known to have higher serum concentrations of 
CTX compared to pre-menopausal women (30–33). This increased serum level may be 
reflection of the increase in bone resorption rates seen in post-menopausal women, which 
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influences the rate of bone turnover, leading to consequential bone loss in older women 
(30–33). 
Resting sclerostin was significantly higher in post-menopausal women compared 
to the younger women, and this difference is quite possibly associated with the 
significantly lower resting estrogen levels also found in the post-menopausal women 
when compared to the younger women. As women age and enter menopause, a 
significant decrease in circulating estrogen is observed, which in turn has been associated 
with higher serum sclerostin concentrations (47,105–107). The lower estrogen found in 
our group of post-menopausal women confirms the association of estrogen with 
sclerostin, as these results are in agreement with previous studies that indicate a negative 
correlation between estradiol and sclerostin serum levels (5,43,47,105–107). This is 
important because the younger women were in the follicular phase of their menstrual 
cycle when estrogen are lower, thus at the closest possible level to that of their older, 
post-menopausal, counter parts. In addition, testing all younger women during their 
follicular phase allows for consistency in the levels of estrogen within the younger group 
because of the possible differences in the bone response to exercise at the different phases 
of the menstrual cycle. 
In contrast, DKK-1 concentrations at rest (i.e., pre-exercise) were significantly 
higher in the younger (pre-menopausal) women compared to the older (post-menopausal) 
women. These findings contradict a previous study by Coulson et al., who found resting 
DKK-1 concentrations to be lower in younger women compared to older women (108). 
Furthermore, at baseline, pre-menarcheal girls, who have lower estrogen levels, 
demonstrated higher DKK-1 serum concentrations compared to older post-menarcheal 
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girls (80). Based on this previous literature, one would predict that the post-menopausal 
women would have a significantly higher level of DKK-1 at rest. This difference between 
the studies may be due to the fact that DKK-1 is not bone specific like sclerostin, and so 
free DKK-1 concentrations may be indicative of other functions such as muscle damage 
occurring during the protocol (109). This makes it difficult to make sensible conclusions 
based on these contradicting studies. However, due to DKK-1’s relation to bone 
metabolism, this is a sensible supporting measure to other more concrete markers. This 
data in combination with CTX, sclerostin and OPG allows for a large picture of what may 
be occurring at a cellular level during plyometric exercise. 
Resting OPG was significantly lower in the younger (pre-menopausal) women 
compared to the older (post-menopausal) women. This finding contradicts expectations of 
this osteokine, as OPG is a bone protector that acts as deterrent receptor to the bone 
resorption osteokine RANKL (4,57,55,56,58). As well, estrogen simulates the secretion 
of OPG, which has been demonstrated to be lower in the post-menopausal women, and 
the reduction in estrogen increases the likelihood for the RANKL-RANK interaction to 
occur, increasing bone resorption mechanisms (4). Therefore, OPG was anticipated to be 
higher in the younger women compared to the older women (4,57,55,56,58). However, 
using the same plyometric acute protocol, Dekker et al. found no significant differences 
in resting OPG between the pre- and post-menarcheal girls regardless their differences in 
estrogen (80). It is postulated that the higher levels of OPG found in post-menopausal 
women were a possible protective measure of bone formation that may be influenced by 
outside measures that were not taken in to consideration in this project. As such, more 
observation is needed to determine a definitive pattern between the age groups. 
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5.2 Bone Markers and Osteokines in response to exercise 
 
The response of CTX to a single bout of plyometric exercise was attenuated and 
not significant over 24h post-exercise in the older women. In contrast, our results show 
that a single bout of plyometric exercise, altered serum CTX concentrations in younger, 
pre-menopausal women over 24 hours. In comparison to baseline measures of serum 
CTX, a significant increase was observed at 5 min post-exercise in the younger group. 
However, in a group of males and females, no changes were seen post-exercise when 
performing progressive cycling bouts (85). This can be explained possibly by the 
difference in of modality and the lower intensity level of exercise. The influence an 
exercise protocol has on a specific bone marker is impacted by intensity, modality, and 
duration of the intervention. More intense, impactful exercise is predicted to have a 
greater response compared to a lighter form of exercise. When exercise induces increased 
level of mechanical strain on bone, a larger magnitude of response occurs. For instance, 
weighted, increased repetitions, and more singular exercises may have caused a larger 
response compared to what was seen post-exercise in the women in our study. As such, 
more research is needed to determine concrete conclusions and what threshold needs to 
be reached in order to produce the desired response in osteokines and markers of bon 
turnover (85,88–91). Furthermore, a catabolic response leading to higher resorption, 
marked by an increase in CTX post-exercise, may complement the process of 
remodelling, as an increased breakdown is followed by higher bone formation (1,2,4). 
Therefore, the effect that plyometric exercise is having on CTX in younger women is 
indicative of an increase in bone turnover rate (1,2,4). The CTX increase 5 min post- 
exercise, was then followed by a return to baseline. It is postulated that although there 
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was no post-exercise decrease in CTX in acute exercise, a long-term training intervention 
could lead to an overall decrease of CTX (85,88–91). However, more research is needed 
to understand the timing of such responses. 
A significant time effect and a significant group-by-time interaction in sclerostin 
concentrations were found, suggesting that sclerostin responds to the acute plyometric 
exercise differently between these two groups of women. Sclerostin had no significant 
changes post-exercise in older women. This has been previously demonstrated in post- 
menopausal women during a 12-month resistance and aerobic exercise training 
intervention, and therefore could be validated, as no response was shown post-exercise 
(98). However, in younger women, sclerostin significantly decreased from 5 min to 1h 
post-exercise, then significantly increased to near resting levels 24h post-exercise. This 
decrease in post-exercise levels of sclerostin indicates an exercise-induced upregulation 
of Wnt-signalling, favouring bone formation in young women. A similar, but not 
significant, decrease was previously found in pre- and post-menarcheal girls in response 
to a similar plyometric exercise protocol (80). However, in young men, sclerostin 
concentrations have been found to increase from pre- to 5 min following plyometric 
exercise (81). This indicates a sex difference in the osteogenic response to plyometric 
exercise between young men and women of the same age range and physical activity 
levels. It is also interesting that not only was the direction of the response different but 
the timing as well. Specifically, men had higher sclerostin 5 min post-exercise whereas 
women had no change in sclerostin 5 min post-exercise but saw a decrease from 5 min to 
1h post-exercise (81). 
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In younger (pre-menopausal) women, DKK-1 did not change 5 min post-exercise 
but then significantly decreased from 5 min to 1h and 24h post-exercise, indicating a late 
post-exercise response. In the older (post-menopausal) women DKK-1 significantly 
decreased from pre- to 5 min and 1h post-exercise, then increased back to near resting 
levels 24h post-exercise, indicating an immediate post-exercise response. Overall, an 
exercise-induced decrease in DKK-1 seems to be consistent across age groups in females, 
as an immediate decreasing post-exercise trend was also observed in pre- and post- 
menarcheal girls (80). We speculate that these differences in the timing of the response 
may be related to estrogen. Our pre-menopausal women, who have a later post-exercise 
decrease, have a higher level of estrogen compared to all other age groups, i.e., the pre- 
and post-menarcheal girls, and the post-menopausal women, who have a similar 
immediate response in DKK-1. These observations could be indicative of an age-related 
timing of the DKK-1 response to high impact exercise influenced by circulating levels of 
estrogen. This could be due to the higher estrogen levels in the pre-menopausal women 
creating a protective measure, not allowing DKK-1 to inhibit the Wnt pathway, allowing 
for more potential formation to occur compared to the other groups which would decrease 
the serum levels of DKK-1. However, due to the nature of DKK-1, these results could be 
influenced by the breakdown of muscle, a by-product of muscle damage, occurring in all 
populations during the exercise protocol and this influence should be taken in to 
consideration. No other study to date has assessed the DKK-1 response to exercise and a 
more cellular explanation is needed in order to make definitive conclusions. 
 
Younger women had no OPG response post-exercise, whereas older women had a 
significant  continuous  decrease  from  baseline  to  up  to  24-hours  post-exercise.  The 
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difference in post-exercise response between the groups was reflected in by the 
significant group-by-time interaction. As OPG is considered a protective osteokine 
(4,57,55,56,58), a higher level of OPG in post-menopausal women may be reflective of 
either an age response to bone metabolism or a result to a decrease in RANKL 
concentrations. Indeed, RANKL decreased between 1h and 24h post-exercise in both pre- 
and post-menarcheal girls using a similar protocol leading to an increase in OPG/RANKL 
ratio (80). It can be speculated that a decrease in OPG levels may be indicative of a larger 
decrease in RANKL, and therefore, leading to an overall anabolic increase in their ratio 
(4,57,55,56,58). However, RANKL was not measured in our study. Moreover, the post- 
exercise response was only found in the older group, and not in the pre-menopausal 
women, which indicates an age-related response to an acute bout of plyometric exercise. 
 
 
 
5.3 Strengths and Limitations 
 
This study had several strengths. Having the visits scheduled in the morning 
allowed us to control for circadian rhythm variability. In addition, the measurement of 
jump height (more specifically in the older women) resulted in a safe box jump height 
adjusted to each participant’s jumping ability so not to cause over exhaustion or increased 
chance of falling. A significant strength was the measurement of post-exercise plasma 
changes. We found no significant changes in plasma volume across time; thus, the 
observed differences in the concentrations of osteokines were not influenced by changes 
in plasma volume. 
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The study also has some limitations. First, the sample of 20 women per group was 
a limiting factor. Most of the markers were normally distributed, however CTX was not 
and the use of non-parametric statistics prevented the direct comparison between groups 
for the repeated measures. Second, physical activity status was self-reported, and we 
found our groups included a range of less active individuals and more active individuals, 
which could skew the effect of the exercise protocol. As well, due to a defect in the 
ELISA kits for P1NP we were unable to measure P1NP, which is a direct marker of bone 
formation, and this limits our ability to have a complete and clear interpretation on the 
effect of sclerostin and DKK-1 on bone turnover. 
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CHAPTER 6: CONCLUSIONS AND RECOMMENDATIONS 
 
 
6.1 Conclusions 
 
This study is the first to determine significant differences in bone markers and 
Wnt-influencing osteokines between younger and older women both at rest and in 
response to an acute bout of plyometric exercise. At rest, post-menopausal women had 
significantly higher CTX, sclerostin, and OPG concentrations, and lower DKK-1 serum 
concentrations compared to the younger (pre-menopausal) women. Plyometric exercise 
induced an osteokine response and a bone turnover response over a 24-hour period in 
both groups, but with differences in the timing of this response. CTX significantly 
increased immediately post-exercise in younger women; however, no response was seen 
in older women. Sclerostin significantly decreased post-exercise in the younger (pre- 
menopausal) women, but not in the post-menopausal group. DKK-1 significantly 
decreased post-exercise in both groups, but this response was delayed and prolonged for 
up to 24h in the younger women. OPG significantly decreased post-exercise but only for 
the older women. Overall, these results suggest that age, especially menopause, is an 
important factor of bone’s response to a plyometric exercise protocol in women. 
 
These findings are significant and should be used to further knowledge about 
bone turnover and osteokines in response to exercise. Further research should be done to 
understand the mechanisms involved and if the changes in markers are physiologically 
meaningful in terms of changes in bone structure, density or remodelling. As well, an 
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exercise training intervention is needed to examine whether the responses found in this 
acute exercise study can be influential long-term. 
6.2 Future Directions 
 
The current study examined the effect of a single bout of plyometric exercise in 
younger and older women. A previous study observed the effect of the same exercise in 
young men and boys. An age difference was seen between the younger and older women, 
specifically in sclerostin concentrations, and in the boys and men, while there were also 
differences observed in the osteokine response to exercise. Therefore, a proposed future 
study should examine the osteokine response in older men to complete all age groups. It 
would be interesting to see if indeed the bone response of serum markers of bone 
turnover and osteokines to exercise is age-dependent also in men as seen in women. 
In addition, a plyometric exercise intervention, either short-term or long-term, 
should be considered. It would be fascinating to determine if there could be either a 
training effect, a lasting effect, or an overall impact on the Wnt signalling related 
osteokines as a direct result of the short-term or long-term plyometric training. 
Furthermore, detecting variations in osteokine alterations would be interesting and 
informative. Do duration, intensity and type of exercise matter? Comparing different 
training modalities, durations, and intensities would be very interesting: is the response of 
a different magnitude? These are questions that can be examined by a short-term or long- 
term plyometric training protocol. 
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Appendix 1: Recruitment Material 
Young Women Recruitment Poster 
 
 
 
 
Participants needed for 
Exercise & Bone Research 
Who: Women over the age 18 years 
Why: To determine the effect of exercise on 
bone turnover 
What is involved:  Two visits to the lab (90 min + 15 
min) 
An exercise session and blood samples before 
and after exercise. 
$20 honorarium for participating. 
Contact Kate Nelson 
905 688-5550 ext. 5623 OR kn10ko@brocku.ca 
This study has been reviewed and received clearance from the Brock University Research 
Ethics Board (file #14-267 ) – reb@brocku.ca, 905-688-5550 ext 3035. 
Principal Investigator, Dr. Nota Klentrou, Department of Kinesiology, can be contacted at 
905 688-5550 (ext. 4538) OR nklentrou@brocku.ca 
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RIGHTSOF R ESEA.RCH PA RTICI PA.N TS 
 
You wiU receive a sigoed copy of thisconseot 01m.You may withdraw your conseot to participate in this 
shidy at any time, and you may also discontinue participation at aoy time without peoalty.In signifl.$ this 
consent form 01in pa rlic-ipa ting: in this St'l.l dy you are not waiving any legal claims or remedies.This study 
has b-eeo r eviewed aod received clearance from the Brock University Re search Ethic-s Board (lite u RE8 
14·2671.11v ou have any pertinent quest ions abou t yOut ri$hts asa r esearch participaot, please cootact 
the 8roc-k Uoiversity Research Ethics Ollicet (90S688 5550  JOJS, reb@brock u . ). 
 
INFORM.ATI ON 
 
Please contact Ot.N ota at  906688 5550 4538, ok?.eotrou@ brock u .ca 01 Kate Nelsoo at 90S 
688  5550 S62l, knlOko@ brocku. ca if you have any questions abou t this St'l.ldy. 
 
 
 
I HAVE READ AND UNDERSTAND THE ABOVE EXPLANATION OF THE PURPOSE ANO 
PROCEDURES OF THE PROJECT. I HAVE ALSO RECEIVED A SIGNED COPY OF THE 
INFORMATION ANO C-ON SENT FORM. MY QUESTIONS HAVE BEEN AN SWERED TO MY 
SATISFACTION AND I AGREE TO PAR TICIPA TE l.N THIS STUDY. 
 
 
 
 
   
SIGN ATUR E OF PARTICIPAN T DATE 
 
 
 
 
 
 
PRINTED NAME Of PARTICIPANT 
 
 
 
 
 
   
WITN ESS DATE 
 
In my judement the participant is voluntarily and knowingly giving informed consent and 
possesses the legal capacity to give informed consent and participate in thisresearch st ud'y. 
 
 
 
 
   
SIGN ATUR E Of  INVE STIGATOR DATE 
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Physician Medical Consent Form 
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Appendix 3: Questionnaires 
 
 
SUBJECT SCREENING AND MEDICAL HISTORY QUESTIONNAIRE 
 
 
 
Name:      Date:    
 
Date of Birth:    
 
Dominant Hand:    Dominant Leg:    
 
Your responses to this questionnaire are confidential. If you answer “YES” to any of the following 
questions, please give additional details in the space provided and discuss the matter with one of the 
investigators. You may refuse to answer any of the following questions. 
 
1. Have you ever had any major joint instability or ongoing chronic pain such as 
in the knee, back or elbow? 
YES NO 
 
2. Are you currently taking any medication (including aspirin) or have you taken 
any medication in the last two days? 
YES NO 
 
3. Have you taken any medication in the past six months? YES NO 
 
4. Is there any medical condition with which you have been diagnosed and are 
under the care of a physician (e.g. asthma, diabetes, anorexia)? 
YES NO 
 
5. Do you, or have you in the past, consumed any alcohol on a regular basis? YES NO 
 
6. Do you, or have you in the past, smoked on a regular basis? YES NO 
 
7. Are you, or have you in the past, engaged in any extreme diet? YES NO 
 
8. Do you, or have you in the past, engaged in physical activity on a regular 
basis? 
YES NO 
 
9. Have you had any fractures? YES NO 
 
10. FEMALES ONLY: Have you had your period? YES NO 
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GODIN-SHEPHARD  LEISURE-TIME  EXERCISE  QUESTIONNAIRE 
 
 
 
1. Considering a 7-day period (a week), how many times on the average do you do the following 
kinds of exercise for more than 15 minutes during your free-time (write on each line the 
appropriate  number)? 
 
 
Per 
Week 
 
(a) STRENUOUS  EXERCISE 
(HEART BEATS RAPIDLY) 
Times 
 
 
(i.e. running, jogging, hockey, football, soccer, squash, basketball, 
cross country skiing, judo, roller skating, vigorous swimming, 
vigorous long distance bicycling) 
 
(b) MODERATE  EXERCISE 
(NOT EXHAUSTING) 
 
 
(i.e. fast walking, baseball, tennis, easy bicycling, volleyball, 
badminton, easy swimming, alpine skiing, popular and folk dancing) 
 
(c) MILD EXERCISE 
(MINIMAL EFFORT) 
 
 
(i.e. yoga, archery, fishing from river bank, bowling, horseshoes, 
golf, snow-mobiling, easy walking) 
 
 
 
 
2. Considering a 7-day period (a week), during your leisure-time, how often do you engage in any 
regular activity long enough to work up a sweat (heart beats rapidly)? 
 
 
1. OFTEN 2. SOMETIMES 3. NEVER/RARELY 
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Appendix 4: Data Collection Sheet 
 
ANTHROPOMETRIC  MEASUREMENTS 
 
 
 
 
 
Height (cm): Jump Height (cm): 
Weight (kg): W:H Ratio: 
BMI: % Body Fat: 
Hip Circumference (cm): Waist Circumference (cm): 
 
 
Hematocrit   Measurements 
 
Draw 1 2 3 4 
Percent     
 
 
 Time of Blood Draw 
 
Draw 1 2 3 4 
Time     
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Appendix 5: Raw Data 
Anthropometric Measurements 
Participant 
ID 
 
Age 
Pre vs. Post- 
menopausal 
Height 
(cm) 
Weight 
(kg) 
 
% BF 
 
BMI 
 
WC 
 
HC 
W:H 
Ratio 
S01 (201) 23 1.00 174.2 64.2 26.8 21.2 70.5 85.5 0.82 
S02 (202) 22 1.00 161.3 62.9 22.6 24.3 72.5 74.5 0.97 
S03 (203) 24 1.00 159.9 46.2 28 18 65.5 78.5 0.83 
S04 (204) 24 1.00 165.9 62 25.6 22.5 69.5 90.5 0.77 
S05 (205) 20 1.00 151.5 54.9 36 24.1 65.5 75.5 0.87 
S06 (206) 23 1.00 163 58.1 16.9 21.9 67 81.5 0.82 
S07 (207) 22 1.00 165.5 63.3 24.7 23 72.5 87.5 0.83 
S08 (208) 21 1.00 151.1 50.8 24 22 64.5 77.3 0.83 
S09 (209) 22 1.00 180.8 62.9 20.4 19.2 67 92.7 0.72 
S10 (210) 28 1.00 178 61.6 18.2 19.4 63.5 83 0.77 
S11 (211) 22 1.00 168 69.6 28.9 24.7 74.5 96.8 0.77 
S12 (212) 22 1.00 168.3 54.4 16.5 19.2 65.5 78 0.84 
S13 (213) 26 1.00 153 55.3 26.9 23.6 72 82 0.88 
S14 (214) 27 1.00 174.1 65.2 19.6 21.5 74.7 94.7 0.79 
S15 (215) 24 1.00 163.5 67 31.4 24.9 70.5 99 0.71 
S17 (217) 23 1.00 161 58.4 21.6 22.6 73 92.5 0.79 
S18 (218) 25 1.00 172.8 85.3 34.2 26.9 87.5 113.5 0.77 
S19 (219) 24 1.00 157.9 66.2 28.9 26.5 72.4 105.5 0.69 
S20 (220) 25 1.00 161.5 63.7 27 24.3 73 103 0.71 
S21 (221) 18 1.00 171.4 74.4 14.9 25.8 78.5 103.5 0.76 
S22(222) 21 1.00 177.1 68.9 25.8 22 84.5 101.5 0.83 
W01 (301) 56 2.00 172.9 67 21.5 22.4 73 102.7 0.71 
W02 (302) 58 2.00 169.1 79.1 39.2 27.7 91.5 112.5 0.81 
W03 (303) 54 2.00 151.5 49.1 21.65 21.2 74 86 0.86 
W04 (304) 54 2.00 172.9 67.4 22.35 22.75 72.5 93.5 0.78 
W05 (305) 68 2.00 155.5 73.4 43.1 30.4 86.5 107.5 0.80 
W06 (306) 65 2.00 158 53.2 28.85 21.3 73 94.5 0.77 
W07 (307) 58 2.00 160.7 56 27.1 21.6 77 94.8 0.81 
W08 (308) 62 2.00 158.3 71.4 39.8 28.5 84.5 112.2 0.75 
W09 (309) 58 2.00 166.3 71.5 33.4 26 96 97 0.99 
W10 (310) 58 2.00 153.9 78.6 50.3 33.1 93 117 0.79 
W11 (311) 57 2.00 176 74.7 25.5 24.3 78 99 0.79 
W12 (312) 52 2.00 162.8 60.5 22.8 26.7 78 90 0.87 
W13 (313) 59 2.00 170.6 61 19.5 20.95 68 94.5 0.72 
W14 (314) 55 2.00 168.8 61.7 31.4 21.6 75.5 96.2 0.78 
W15 (315) 59 2.00 170.3 79.8 35.5 27.6 82.2 111.5 0.74 
W16 (316) 52 2.00 157.5 63.5 39 25.8 80.3 105.5 0.76 
W17 (317) 65 2.00 164.9 70.5 34.4 25.9 84 101.2 0.83 
W18(318) 55 2.00 168.3 56.2 29.4 19.85 70.5 92.8 0.76 
W19 (319) 54 2.00 159.4 57.1 21.2 22.5 67.5 92.3 0.73 
W20 (320) 59 2.00 160.2 60.8 33.8 23.8 79.1 94.8 0.83 
 
90  
Activity, Jump and bone SOS data 
 
 
Participant 
ID 
Physical 
Activity 
Mets/Week 
Jump 
Height 
(cm) 
 
Box Height 
(cm) 
Percent of 
Jump Height 
(%) 
 
 
SOS Rad 
 
 
SOS Tib 
S01 (201) 121 31.5 35 112.8888889   
S02 (202) 109  35    
S03 (203) 55  35    
S04 (204) 27  35    
S05 (205) 116  35    
S06 (206) 66  35    
S07 (207) 82 37 35 96.10810811   
S08 (208) 20  35    
S09 (209) 59 29 35 122.6206897   
S10 (210) 56 33 35 107.7575758   
S11 (211) 46  35    
S12 (212) 39 32 35    
S13 (213) 82  35    
S14 (214) 72 37.2 35 95.59139785   
S15 (215) 167 28 35 127   
S17 (217) 54 31.2 35 113.974359 4034 3957 
S18 (218) 47 28.1 35 126.5480427 4089 3838 
S19 (219) 40 38.3 35 92.845953 4098 3943 
S20 (220) 122 38.9 35 91.41388175 4028 3999 
S21 (221) 45 38.9 35 91.41388175 4107 3928 
S22(222) 161  35  4139 -3904 
W01 (301) 37 30.6 35 114.379085 4032 3784 
W02 (302) 57 26.4 30 113.6363636 3891 4087 
W03 (303) 79 25 30 120 4007 3861 
W04 (304) 95 24 25 104.1666667 3919 3870 
W05 (305) 55 20 25 125 3916 3966 
W06 (306) 60 18 25 138.8888889 4099 3907 
W07 (307) 112 24 25 104.1666667 3756 3983 
W08 (308) 76 17 25 147.0588235 4030 3878 
W09 (309) 51 28.6 30 104.8951049 4075.0 3839 
W10 (310) 45 16.3 25 153.3742331 4183.0 3930 
W11 (311) 12 28.6 30 104.8951049 4126.0 3962 
W12 (312) 11 20 25 125 4205.0 3755 
W13 (313) 48 20 25 125 4026.0 3892 
W14 (314) 106 27.3 30 109.8901099 3959.0 4027 
W15 (315) 144 20.7 25 120.7729469 4021.0 3876 
W16 (316) 28 21 25 119.047619 4385.0 4064 
W17 (317) 154 24 25 104.1666667 3894.0 3903 
W18(318) 45 22 25 113.6363636 4040.0 3968 
W19 (319) 116 22 25 113.6363636 4110.0 3812 
W20 (320) 84 19.3 25 129.5336788 4034.0 3994 
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Serum and Plasma Measurements 
 
Participant 
ID 
Plasma 
A 
Plasma 
B 
Plasma 
C 
Plasma 
D 
 
SOST A 
 
SOST B 
 
SOST C 
 
SOST D 
S01 (201)     175.6 261 161  
S02 (202)     165.2 469.3 356.6  
S03 (203)     127 78.76   
S04 (204)     203.1 243.3 218.1  
S05 (205)     328.2 418.9 235.5  
S06 (206)     170.2 220.7 135.8 134.6 
S07 (207)     137.8 313.2 335.5 450.3 
S08 (208)     417 737.7 335.3  
S09 (209)     529.1 473.8 290.4 272.8 
S10 (210)     318.7 187.2 238.9 375 
S11 (211)     261.1 110 120.7 207.1 
S12 (212)     261.7 329 213.8  
S13 (213)     195.3 406.5 278.9 169.5 
S14 (214)     163.6 360.6 160.9 146.3 
S15 (215)      63.3 71.89 123.9 
S17 (217)     92.04 189.7  156.6 
S18 (218)     126.3 218.3 302.1 253 
S19 (219) 0.52 0.65 0.66 0.65 314.4 388.6 501.2 435.6 
S20 (220) 0.62 0.62 0.625 0.634 49.8 106 52.22 228.5 
S21 (221) 0.63 0.61 0.624 0.624 335 370.8 404.6 296.5 
S22(222) 0.58 0.57 0.58 0.6 62.07 81.46 69.74 127.2 
W01 (301) 0.66 0.65 0.65 0.68 724.3 1004 872.3 1392 
W02 (302) 0.52 0.52 0.53 0.53 1047 747 611.4 1350 
W03 (303) 0.57 0.59 0.6 0.605 557.9 526 484.9 1158 
W04 (304) 0.55 0.55 0.55 0.57 389.6 304.2 314.7 381.1 
W05 (305) 0.575 0.55 0.57 0.58 602.5 653 780.7 816.1 
W06 (306) 0.57 0.57 0.58 0.57 1033 979.3 1407 867.9 
W07 (307) 0.53 0.56 0.55 0.55 160.5 353.5 245.4 547.7 
W08 (308) 0.59 0.58 0.59 0.6 584.2 351.8 403.3 697.4 
W09 (309) 0.57 0.56 0.57 0.55 701.9 631.7 430.9  
W10 (310) 0.58 0.57 0.58 0.57 806.6 720.4 830.5 756.3 
W11 (311) 0.57 0.57 0.57 0.58 572.5 595.7 905.7 791.9 
W12 (312) 0.58 0.56 0.57 0.6 623.4 799.3 689.9 827.5 
W13 (313) 0.583 0.575 0.575 0.6 713.3 607.4 333.5 372.6 
W14 (314) 0.6 0.59 0.595 0.592 666.3 721.6 862.1 783 
W15 (315) 0.597 0.594 0.607 0.599 722.4 402.5 616.4 573.9 
W16 (316) 0.607 0.59 0.58 0.6 339 404.1 338.9 515.2 
W17 (317)    1 162.6 212 400.4 308.5 
W18(318) 0.6 0.59 0.6 0.61 280.9 193.5 405.4 354.9 
W19 (319) 0.56 0.55 0.55 0.55 162.6 188.3 391.3 133.1 
W20 (320) 0.56 0.56 0.56 0.56 411.5 630.6 523 524.9 
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Participant 
ID 
 
DKK-1 A 
 
DKK-1 B 
 
DKK-1 C 
 
DKK-1 D 
 
Leptin A 
 
Leptin B 
 
Leptin C 
 
Leptin D 
S01 (201) 1385.93 2419.89   4105.95 4335.88   
S02 (202) 2450.37 2724.49 2092.28  5111.24 2941.68 2662.42  
S03 (203) 1805.37 1891.11 1563.56 1805.37 3282.78 2770.3 2328.85 2519.76 
S04 (204) 2208.07 1754.64 1998.84 1861.59 5903.75 3816.76 4498.15 3655.86 
S05 (205) 2308.14 2642.88 2239.54 2142.59 4723.7 4225.34 3571.33 4370.17 
S06 (206) 2008.33 2085.74 1768.69 1777.02 1597.02 1372.31 1143.77 1967.08 
S07 (207) 2705.3 2575.6 2381.11 2539.73 4392.53 3630.2 3390.09 3449.97 
S08 (208) 2874.75 3207.36 2687.86  8385.13 7520.43 7339.93  
S09 (209) 2484.56 3066.04 2701.16  1448.06 1096.46 968.67  
S10 (210) 2705.3 2935.97 2503.87 2530.07 3576.07 3109.99 2785.4 3254.95 
S11 (211) 3819.27 4014.4 3479.32 3568.44 6264.64 5012.04 4169.32 5002.89 
S12 (212) 3304.89 3625.43 3457.06  2476.75 2064.42 1884.09 1640.99 
S13 (213) 2244.26 2455.33 2235.94 2277.37 6102.91 5309.43 4386.01 4666.85 
S14 (214) 3127.59 3417.47 2767.5 2326.56 2994.56 2599.76 1898.26 1731.85 
S15 (215)  2904.86 2550.46 2445.35  7651 6582.13 6115.98 
S17 (217)  1102.96  1064.01  2544.74  2769.1 
S18 (218)         
S19 (219) 2025.86 2348.42 2149.79 2349.5 5215.76 4648.65 4208.26 4451.84 
S20 (220) 1688.86 1985.75 1894.17 2111.58 4581.13 4225.31 3928.57 4412.21 
S21 (221) 1801.84 1485.43 1582.39 1424.98 11186.17 10127.91 8756.61 9287.23 
S22(222)         
W01 (301) 1420.03 1513.42 854.34  4856.15 4383.66 3978.03  
W02 (302) 2494.8 2880.44 2128.98 2544.94 15160.58 15119.38 13168.41 11812.04 
W03 (303) 758.74 1091.25 1004.39 1049.74 2527.18 2429.38 2559.3 3730.57 
W04 (304) 1872.69 1975.14 1476.21 1541.87 4192.31 3387.55 2840.85 4305.68 
W05 (305) 1166.6 1366.27 872.43 1706.7 14773.92 14734 13142.83 13613.81 
W06 (306) 2466.63 2349.38 1320.59 2323.17 948.05 834.63 804.33 759.24 
W07 (307) 2049.81 1928.09 1379.58 1441.24 4869.95 4292.39 4027.66 5060.81 
W08 (308) 1502.77 635.54 746.8 953.26 7248.01 3273.31 4994.2 8731.33 
W09 (309)         
W10 (310) 1049.26 1021.81 978.42 1009.13 21346.82 17049.56 15261.96 21771.58 
W11 (311) 1675.61 1650.57 1569.77 1608.8 3145.01 2622.19 2804.22 3456.7 
W12 (312) 2733.11 2724.18 2653.67 2771.31 3305.52 2863.97 2798.06 3707.2 
W13 (313) 3318.5 3009.24 2792.89 3324.69 1993.49 1400.1 1377.07 1509.9 
W14 (314) 2645.94 2825.82 2349.6 2607.2 3543.52 3070.37 2553.75 2909.24 
W15 (315) 2951.69 2483.09 2685.79 2685.79 17928.14 13248.28 13914.88 10636.01 
W16 (316) 2763.68 2442.06 2735.66 2669.1 9050.12 7528.22 7882.65 8623.09 
W17 (317) 1148.12 1061.91 557.44 773.92 3607.72 3241.33 2269.35 2955.81 
W18(318) 1752.63 964.63 633.6 1830.14 6947.44 2826.82 4059.47 4287.85 
W19 (319) 1323.82 1110.32 1156.51 1029.2 1188.88 984.23 830.76 819.75 
W20 (320)         
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Participant 
ID 
 
OPG A 
 
OPG B 
 
OPG C 
 
OPG D 
 
Estradiol 
S01 (201) 328.77 417.23   126.1 
S02 (202) 389.35 283.32 280.67  168.9 
S03 (203) 255.65 251.8 262.87 281.15  
S04 (204) 339.35 281.63 341.99 340.55 67.4 
S05 (205) 387.91 387.43 433.09 422.51 54.07 
S06 (206) 440.76 408.86 411.8 393.51 88.27 
S07 (207) 261.29 254.9 256.6 277.25 130.3 
S08 (208) 725.28 668.17 616.56  230.6 
S09 (209) 367.19 370.35 422.09  46.72 
S10 (210) 311.41 298.26 330.45 308.86 112.7 
S11 (211) 403.3 413.6 405.02 429.02 56.39 
S12 (212) 533.75 573.02 632.69 443.62  
S13 (213) 430.73 471.66 477.33 485.82 52.07 
S14 (214) 370.28 344.3 339.38 281.1  
S15 (215)  552.71 623.17 440.09  
S17 (217)  315.69  303.45  
S18 (218)     79.42 
S19 (219) 358.62 356.87 448.92 392.47 79.68 
S20 (220) 412.29 466.17 476.58 668.8 72.94 
S21 (221) 364.33 353.8 351.6 356.87 67.26 
S22(222)     122.8 
W01 (301) 629.05 668.41 566.15  43.79 
W02 (302) 453.27 476.09 452.79 467.2 77.17 
W03 (303) 328.53 323.48 347.04 321.08 66.29 
W04 (304) 458.57 442.86 326.22 397.93 27.89 
W05 (305) 450.87 480.17 484.98 461.44 68.05 
W06 (306) 722.6 619.48 625.91 625.91 59.39 
W07 (307) 589.99 536.08 543.58 565.65 68.08 
W08 (308) 448.93 197.37 367.4 439.5 28.91 
W09 (309)      
W10 (310) 514.49 471.93 489.42 505.61 84.46 
W11 (311) 468.83 435.94 514.18 500.19 73.37 
W12 (312) 933.21 826.04 773.49 836.69 78.03 
W13 (313) 778.43 673.47 685.92 740.25  
W14 (314) 510.11 561.26 505.31 506.72  
W15 (315) 644.92 532.63 551.16 567.98 94.02 
W16 (316) 518 398.72 514.62 512.92 83.04 
W17 (317) 333.63 301.27 261.18 260.31 83.03 
W18(318) 410.97 175.96 319.63 367.62 84.82 
W19 (319) 449.81 430.59 391.15 478.13 48.36 
W20 (320)     76.35 
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Dietary Data 
 
Participant 
ID 
 
Carbohydrate 
Carbohydrate 
as % of cals 
 
Cholesterol 
Dietary 
Fiber 
Alcohol 
% of cals 
Sweets 
%of cals 
Vitamin 
A 
Beta- 
carotene 
Vit 
C 
S01 (201) 313.82 0.5036 319.07 33.94 0.0145 0.0571 1494.09 10682.47 27 
S02 (202) 144.36 0.4589 329.15 18.72 0.0332 0.2011 1459.01 9387.75 13 
S03 (203) 114.21 0.4188 138.97 7.44 0.0323 0.2342 396.47 1495.94 66. 
S04 (204) 130.41 0.0405 220.63 10.48 0.057 0.1028 534.93 1773.61 13 
S05 (205) 128.73 0.6483 17.89 21.03 0.0279 0.0325 674.33 7797.97 11 
S06 (206) 184.51 0.4866 117.8 17.01 0.00356 0.1872 813.59 2423.81 10 
S07 (207) 154.55 0.4516 127.11 13.72 0.138 0.1606 689.82 5978.87 15 
S08 (208) 200.95 0.0413 216.9 14.79 0.0636 0.2232 628.98 2600.86 48. 
S09 (209) 300.81 0.5643 70.23 24.19 0.0373 0.2914 648.06 1332.87 12 
S10 (210) 174.12 0.4721 140.65 16.74 0.1061 0.0527 526.89 2432.81 32. 
S11 (211) 222.25 0.4282 338.65 23.82 0.0351 0.1564 1342.22 6548.68 16 
S12 (212) 170.62 0.3937 280.37 16.99 0.0341 0.0939 729.27 4659.24 12 
S13 (213) 99.85 0.2453 528.67 20.28 0.00945 0.0571 1493.64 10490.04 13 
S14 (214) 191.44 0.4886 140.83 18.64 0.1495 0.0416 909.02 5448.85 84. 
S15 (215) 137.56 0.4438 319.78 14.88 0.0524 0.1546 1310.86 8073.27 94. 
S17 (217) 354.79 0.4905 211.3 34.9 0.0567 0.1173 859.71 3643.81 26 
S18 (218) 387.91 0.7228 45.15 48.94 0.0154 0.1405 1533.7 15227.41 45 
S19 (219) 209.84 0.4033 285.09 19.63 0.096 0.0852 653.69 2324.37 10 
S20 (220) 128.65 0.4418 261.04 12.39 0.0548 0.1314 734.47 4555.35 57. 
S21 (221) 380.73 0.4625 494.38 36.54 0.0237 0.0926 1940.68 10767 42 
S22(222) 196.09 0.4978 167.58 15.68 0.0621 0.178 592.11 2551.24 12 
W01 (301) 169.47 0.5005 117.82 19.79 0.00379 0.1635 746.84 4919.29 78. 
W02 (302) 146.35 0.4359 254.73 17.24 0.0078 0.0904 851.72 5779.48 56. 
W03 (303) 390.58 0.5465 259.73 47.42 0.00131 0.0524 1414.32 7898.84 44 
W04 (304) 140.51 0.4344 144.92 15.6 0.0577 0.0284 498.56 3251.1 13 
W05 (305) 132.29 0.2999 473.84 32.05 0.0268 0.00677 1232.7 12311.15 17 
W06 (306) 149.93 0.0005 181.1 10.66 0.0104 0.1007 700.16 2298.75 64. 
W07 (307) 262.62 0.5607 149.95 37.24 0.1015 0.0694 512.49 3011.14 10 
W08 (308) 227.83 0.0448 219.37 29.87 0.0204 0.0282 1682 8390.85 17 
W09 (309) 138.86 0.4227 151.72 14.23 0.103 0.0315 944.13 7992.49 10 
W10 (310) 189.72 0.3575 153.76 22.54 0.0735 0.0114 1779.38 14065.06 16 
W11 (311) 232.18 0.4923 162.37 27.1 0.00868 0.1174 2095.61 11021.11 34 
W12 (312) 158.24 0.3939 433.55 24.84 0.00355 0.0362 1512.77 12561.51 18 
W13 (313) 174.03 0.5253 148.53 13.1 0.0268 0.122 388.14 1161.91 14 
W14 (314) 184.44 0.4745 194.23 22.83 0.000774 0.1563 981.54 6125.76 11 
W15 (315) 106.39 0.4002 123.16 13.67 0.1285 0.1049 564.88 3818.22 65. 
W16 (316) 67.56 0.3716 224.53 9.34 0.091 0.0334 395.53 2677.27 69. 
W17 (317) 99.21 0.5049 81.12 7.82 0.0282 0.0959 442.61 1761.05 36. 
W18(318) 149.27 0.0422 164.99 16.72 0.1104 0.0751 662.42 4123.22 10 
W19 (319) 39.52 0.4577 58.47 2.99 0 0.0905 135.84 876.38 14. 
W20 (320) 220.53 0.5323 283.95 35.85 0.0393 0.0633 1660.85 17746.78 26 
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Participant 
ID 
 
Vitamin E 
 
B1, B2 
 
Niacin 
 
Folate 
Vitamin 
B6 
 
Calcium 
 
Zinc 
 
Iron 
 
Potassium 
S01 (201) 10.58 2.44 29.45 682.51 2.62 2289.75 17.19 19.42 4716.49 
S02 (202) 13.73 2.06 27.59 344.25 2.21 763.43 10.21 14.02 2535.19 
S03 (203) 5.21 0.752 13.19 197.72 0.982 534.07 5.62 6.31 1434.26 
S04 (204) 5.66 1.15 15.04 241.05 1.01 628.55 8.08 7.85 2062.33 
S05 (205) 5.8 0.817 7.27 241.77 0.936 407.83 4.39 8.26 1751.83 
S06 (206) 9.29 1.51 18.01 419.63 1.72 1210.58 9.66 11.9 2439.48 
S07 (207) 8.28 1.19 15.01 279.86 1.19 756.13 7.18 9.02 2190.1 
S08 (208) 7.58 1.52 22.67 321.92 1.49 806.18 9.33 11.1 2509.31 
S09 (209) 13.58 2.29 21.91 443.32 1.95 1662.15 13.05 16.1 3001.98 
S10 (210) 4.87 1.9 12.93 308.78 1.31 994.57 8.08 11.11 2417.71 
S11 (211) 11.42 1.77 26.46 417.14 2.37 1617.65 12.07 14.88 3783.63 
S12 (212) 7.38 1.33 22.19 324.06 1.64 709.59 14.09 13.21 2638.19 
S13 (213) 12.2 1.36 18.77 396.23 1.63 742.69 10.81 11.26 2538.16 
S14 (214) 6.19 1.52 16.47 343.41 1.83 1167.37 8.52 9.42 3239.41 
S15 (215) 10.5 1.87 19.08 284.58 1.84 771.51 8.21 12.55 2264.35 
S17 (217) 15.36 2.13 26.42 536.9 2.25 1592.12 15.83 19.27 3941.53 
S18 (218) 14.28 2.98 25.95 752.13 3.34 789.35 11.38 21.8 4752.57 
S19 (219) 7.33 1.68 19.42 381.99 1.66 1256.44 11.75 13.36 2749.05 
S20 (220) 5.39 1.27 11.31 219.95 1.06 872.62 6.86 7.87 1955.01 
S21 (221) 21.88 2.57 38.07 611.23 3.58 1791.58 18.2 22.67 5202.12 
S22(222) 5.08 1.2 13.66 263.1 1.27 803.14 7.46 9.76 2117.24 
W01 (301) 7.04 1.05 13.37 258.41 1.41 710.84 6.96 9.48 2080.65 
W02 (302) 7.04 1.15 10.03 239.79 0.958 795.81 6.45 9.33 1946.64 
W03 (303) 13.47 2.08 21.31 605.06 2.47 1803.84 13.2 19.21 5620.97 
W04 (304) 6.7 1.53 13.96 276.09 1.34 949.05 8.97 9.31 2815.03 
W05 (305) 16.07 1.34 22.69 447.17 2.27 496.22 11.14 12.06 3987.08 
W06 (306) 3.93 1.89 13.98 260.68 1.13 1056.48 9.05 9.9 2744.28 
W07 (307) 7.17 2.39 20.38 424.49 1.71 1152.37 10.64 17.23 3122.04 
W08 (308) 12.2 2.57 23.01 432.35 2.48 1477.29 15.5 21.76 3391.03 
W09 (309) 6.92 1.53 15.59 309.13 1.53 898.19 8.57 8.96 3096.08 
W10 (310) 18.11 1.5 18.86 568.9 2.11 901.67 13.1 15.7 3185.6 
W11 (311) 20.18 2.76 26.05 504.01 2.49 1547.51 13.84 19.22 4339.64 
W12 (312) 12.59 0.988 15.7 413.73 1.94 787.08 8.06 11.58 2953.83 
W13 (313) 6.32 1.8 12.69 304.34 0.999 739.82 7.14 10.55 2276.83 
W14 (314) 7.29 1.77 17.3 341.33 1.45 918.44 9.89 12.95 2597.45 
W15 (315) 5.7 0.921 12.08 252.93 1.06 368.06 6.64 8.4 1920.84 
W16 (316) 3.61 0.519 8 185.99 0.739 357.37 4.47 5.17 1377.77 
W17 (317) 3.17 1.1 7.23 180.54 0.837 813.05 5.77 7.43 1577.25 
W18(318) 7.56 1.37 15.33 261.69 1.19 635.2 7.74 9.49 2324.74 
W19 (319) 1.41 0.263 3.55 70.89 0.265 112.26 1.64 2.38 396.81 
W20 (320) 11.35 1.82 20.94 646.29 2.12 935.76 9.9 16.71 3975.77 
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Participant 
ID 
Sodium 
(salt) 
 
Magnesium 
 
Supl.Vit.A 
 
Supl.Vit.C 
 
Supl.E 
 
Supl.Folate 
 
Supl.Calcium 
 
Supl.Iron 
 
Supl.Zi 
S01 (201) 4762.3 494.59 0 0 0 0 0 0 0 
S02 (202) 1964.21 369.45 909.87 26 8.67 173.31 86.65 35.96 4.77 
S03 (203) 1811.06 157.95 609 200 20.1 0 0 0 20 
S04 (204) 2162.53 200.45 0 19.23 0 0 0 0 0 
S05 (205) 1513.42 208.77 0 0 0 0 0 0 0 
S06 (206) 2170.27 312.58 0 0 0 0 0 0 0 
S07 (207) 2228.82 263.23 0 0 0 0 151.64 0 0 
S08 (208) 3221.74 261.85 0 0 0 0 0 0 0 
S09 (209) 2143.33 480.82 1539.78 43.99 14.66 293.29 146.65 13.2 8.07 
S10 (210) 2033.05 278.18 0 0 0 0 46.15 47.66 0 
S11 (211) 2964.36 420.33 0 0 0 0 0 0 0 
S12 (212) 4458.85 264.91 0 0 0 400 0 0 0 
S13 (213) 2687.23 291.82 0 767.51 0 114.29 0 0 36.66 
S14 (214) 2385.67 311.6 0 0 0 0 0 0 0 
S15 (215) 1900.25 300.71 0 0 0 0 0 0 0 
S17 (217) 3812.55 509.97 161.54 4.62 1.54 30.77 15.38 1.38 0.846 
S18 (218) 3096.66 567.32 0 0 0 0 0 0 0 
S19 (219) 3428.96 310.85 2100 60 20 400 200 18 11 
S20 (220) 2013.66 228.51 0 0 0 0 0 0 0 
S21 (221) 5529 604.97 0 500 0 0 0 65 0 
S22(222) 2433.4 227.2 0 0 0 0 0 0 0 
W01 (301) 2330.42 245.74 0 0 0 0 85.71 9.29 0 
W02 (302) 3435.67 223.25 0 76.92 0 0 281.63 5 0 
W03 (303) 4100.69 527.23 1200 1120 96.57 800 200 28 15 
W04 (304) 2229.09 251.06 0 0 0 0 0 0 0 
W05 (305) 2598.12 344.56 2100 60 20 400 200 18 11 
W06 (306) 1866.42 262.92 0 0 0 0 0 0 0 
W07 (307) 2218.58 473.4 0 0 0 0 439.94 0 0 
W08 (308) 3266.45 492.81 1986.32 1745.08 29.4 586.58 623.24 13.2 22.73 
W09 (309) 2286.85 272.81 161.54 43.08 1.54 30.77 15.38 1.38 0.846 
W10 (310) 3370.83 416.36 2100 60 20 800 800 18 11 
W11 (311) 2899.27 525.27 3909 1500 60.1 1600 750 46 46 
W12 (312) 2502.54 298.31 0 0 0 0 46.15 0 0 
W13 (313) 1881.68 268.01 161.54 1004.62 39.82 61.54 275.35 6.38 7.99 
W14 (314) 2876.13 299.57 0 0 0 0 0 0 0 
W15 (315) 1777.05 206.36 0 225.87 0 30.77 0 0 0 
W16 (316) 1309.61 132.07 909.87 64.46 85.24 173.31 258.08 7.8 4.77 
W17 (317) 1224.82 164.59 0 0 0 0 0 0 0 
W18(318) 2272.77 248.45 0 0 0 0 0 0 0 
W19 (319) 602.92 40.4 0 0 0 0 600 65 0 
W20 (320) 4436.05 412.9 0 0 0 0 0 0 0 
 
